Washington University in St. Louis

Washington University Open Scholarship
Arts & Sciences Electronic Theses and
Dissertations

Arts & Sciences

Summer 8-15-2016

Infantile Batten Disease: Effective Therapy and Novel Model
Charles Shyng
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds

Recommended Citation
Shyng, Charles, "Infantile Batten Disease: Effective Therapy and Novel Model" (2016). Arts & Sciences
Electronic Theses and Dissertations. 896.
https://openscholarship.wustl.edu/art_sci_etds/896

This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open
Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an
authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Molecular Cell Biology

Dissertation Examination Committee:
Mark S Sands, Chair
John Cirrito
David H. Gutmann
Jin-Moo Lee
Steven J. Mennerick
Daniel S. Ory

Infantile Batten Disease: Effective Therapy and Novel Model
by
Charles Shyng

A dissertation presented to the
Graduate School of Arts & Sciences
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

August 2016
St. Louis, Missouri

©2016, Charles Shyng

Table of Contents
List of Figures ................................................................................................................................ iv
List of Abbreviations ...................................................................................................................... v
Acknowledgements ........................................................................................................................ vi
Abstract of the Dissertation ........................................................................................................... ix
Chapter 1: Introduction ................................................................................................................... 1
Lysosomal Storage Diseases ..................................................................................................................... 2
Neuronal Ceroid Lipofuscinoses ............................................................................................................... 3
Infantile Neuronal Ceroid Lipofuscinosis .................................................................................................. 4
The murine INCL model ............................................................................................................................ 6
INCL Therapy ............................................................................................................................................. 8
Small molecule drugs ............................................................................................................................ 8
Cross-correction .................................................................................................................................... 9
Cell-mediated Therapy ........................................................................................................................ 10
Goals of the Thesis .................................................................................................................................. 12
Spinal Cord pathology ......................................................................................................................... 12
Multiple cell types involved in INCL pathogenesis.............................................................................. 13
Tethered PPT1 to the lysosomal membrane ...................................................................................... 15

Chapter 2: A new and effective therapeutic target for Infantile Batten disease ........................... 17
Introduction ............................................................................................................................................ 18
Material and Methods ............................................................................................................................ 21
Results ..................................................................................................................................................... 27
Intracranial AAV2/9-hPPT1 is superior to AAV2/5-hPPT1. ................................................................. 27
Spinal Cord disease in IC-treated PPT1-/- animals.............................................................................. 28
Spinal Cord Pathology in INCL ............................................................................................................. 29
Summary of Brain and Spinal Cord INCL Pathogenesis....................................................................... 34
Differential PPT1 activity in the brain and spinal cord following intracranial and intrathecal AAV2/9hPPT1 .................................................................................................................................................. 35
Intracranial and Intrathecal AAV2/9-hPPT1 reduce histological markers of INCL .............................. 38
IC-AAV2/9 and IC/IT-AAV2/9 decrease cortical atrophy..................................................................... 39
Combination therapy reduces neuroinflammation in brain and spinal cord ..................................... 41
Improvements in Motor function and Longevity ................................................................................ 45
ii

Discussion................................................................................................................................................ 48

Chapter 3: Cell-limited expression of PPT1 ................................................................................. 53
Introduction ............................................................................................................................................ 54
Materials and Methods........................................................................................................................... 56
Results ..................................................................................................................................................... 61
Lysosomal Membrane-Tethered PPT1 ................................................................................................ 61
PPT1-LAMP1 function in vitro ............................................................................................................. 62
Generation of a PPT1-LAMP1 transgenic animal ................................................................................ 64
Founder #42 analyses ......................................................................................................................... 66
PPT1-LAMP1 expression in vivo is ubiquitous and prevents AFSM .................................................... 68
PPT1-LAMP1 ubiquitous expression in vivo prevents behavioral decline and extends longevity ...... 70
Discussion................................................................................................................................................ 71

Chapter 4: Summary, Conclusions, and Future Directions........................................................... 75
Summary and Conclusions ...................................................................................................................... 76
A new target and effective therapy for INCL ...................................................................................... 76
Conclusion from combination therapy ............................................................................................... 79
Future Directions for INCL gene therapy ............................................................................................ 81
Summary of cell-limited study of PPT1 ............................................................................................... 86
Conclusions from cell-specific expression of PPT1 ............................................................................. 87
Future Directions for Cell-specific Study of INCL ................................................................................ 88

References ..................................................................................................................................... 91
Curriculum Vitae ........................................................................................................................ 108
Academic and Professional Honors ................................................................................................... 110

iii

List of Figures
Figure 1. AAV2/9 is superior to AAV2/5 but does not correct the spinal cord
Figure 2. Progressive accumulation of autofluorescent storage material
Figure 3. Regional Volume measurements of PPT1-/- spinal cords
Figure 4. Progressive astrocytosis in the spinal cord
Figure 5. Progressive microgliosis in the spinal cord
Figure 6. Diagram of temporal pattern of INCL brain and spinal cord pathology
Figure 7. PPT1 and Secondary enzyme activity in treated animals
Figure 8. Histochemical stain for PPT1 activity
Figure 9. Autofluorescent storage material is reduced in the combination treated animals
Figure 10. Cortical atrophy and brain mass is normalized in the combination therapy
Figure 11. Microgliosis is reduced in the combination treated animals
Figure 12. Astrocytosis is reduced in the combination treated animals
Figure 13. Cytokine analysis of treated animals at 7 months
Figure 14. Functional and behavioral phenotype is improved with the combination therapy
Figure 15. Mockup and Sequence of PPT1-LAMP1
Figure 16. In vitro characterization of PPT1-LAMP1
Figure 17. Generation of a cell-specific transgene
Figure 18. Generation of transgenic animals and identification of loxP site recombination
Figure 19. In vitro characterization of F42
Figure 20. Biochemistry and Histology in F42
Figure 21. Functional and Clinical parameters of F42

iv

List of Abbreviations
AAV
AFSM
ANOVA
CNS
ERG
ERT
GFAP
GROD
IC
IC/IT
INCL
IT
LAMP1
LSD
NCL
PBS
PFA
PPT1
PPT1-/S1BF
TBS
VPM/VPL
WT

Adeno-associated virus
Autofluorescent storage material
Analysis of Variance
Central Nervous System
Electroretinography
Enzyme replacement therapy
Glial Fibrillary Acidic Protein
Granular Osmophilic Deposits
Intracranial
Intracranial/Intrathecal
Infantile Neuronal Ceroid Lipofuscinosis
Intrathecal
Lysosome-associated membrane protein-1
Lysosomal storage disease
Neuronal Ceroid Lipofuscinoses
Phosphate-buffered Saline
Paraformaldehyde
Palmitoyl-protein thioesterase-1
PPT1-deficient
Somatosensory barrel field cortex
Tris-buffered saline
Ventral posterior thalamic nucleus
Wild-type

v

Acknowledgements
I could not be at this point in my life without the sacrifice and generosity of my parents,
my family, my thesis advisor, my friends, my beloved fiancé, and my thesis lab members. I am
sincerely thankful for their encouragement and love.
I would like to thank my mom and dad. Without their constant and unwavering support,
love, and encouragement, I would not be where I am today. Their sacrifice so that I could be who
I am today and who I will become tomorrow is not one that can be repaid. I thank them for
instilling in me perseverance and dedication. I thank them for teaching me to see the light and to
find joy when nothing seems to go right. I thank them for teaching me that one never stops
growing. From a young age, they encouraged me to open my mind and explore the world, to
absorb as much knowledge as I could, and to use my talent and skills to help others. I take that
with me every day.
I would like to thank my thesis advisor, Dr. Mark Sands. Mark took me into his lab as a
goofy kid who knew little and has molded me into a well-rounded scientist. He gave me the
opportunity to apply myself and to succeed in graduate school. Mark provided constant guidance
through his open door policy. His willingness to answer my constant questions, listen to my
crazy ideas, help with writing grants and papers, and allowing me to observe daily PI life helped
me to grow scientifically. Mark taught me so much about science and about people. From him, I
learned how to conduct sound basic and translational science. I learned why we perform these
studies. His dedication to helping patients and families is inspirational. His effort to instill that in
his graduate students is commendable. Through scientific and patient conferences, I was able to
see first-hand the impact our work would have on patients and their families. I cannot thank him
enough for these eye-opening opportunities. I thank Mark for believing in and supporting me, for
vi

giving me the opportunity to find my own interests, and for being such an amazing role model
for a goofy kid.
I would like to thank my thesis lab for their laughter and insights. I have learned a great
deal about science and about life from my interactions with current and former lab mates. I
would like to thank Marie for being the awesome ‘lab mom’ and dealing with all the messes and
general craziness. I would like to thank her for helping me get on my feet when I first joined the
lab. Marie has always being there when I had questions or if I just needed someone to talk to. I
would like to thank Kevin for always bringing laughter to my bay. I thank him for working so
diligently, and for teaching me how to run a mouse colony and how to cryosection. I thank
Bruno for being such a great friend both in and out of the lab. I thank him for all the guidance he
has provided with experiments and for being so willing to pass on knowledge.
I would like to thank my closest friends for their constant support and their ability to keep
me grounded. I have had the opportunity to make friends inside and outside of graduate school.
To my friends within the graduate school, I thank you for all the scientific conversations we’ve
had throughout the years and for all the fun times we’ve had outside of lab such as our monthly
food club. I could not imagine going through graduate school without such wonderful friends to
share the experience with. To my friends outside of graduate school, I thank you for all the joys
and laughter. I have watched our circle of friends grow with new additions, with two more tiny
ones on the way. Thank you for keeping me grounded, for continuing to support me through all
of my highs and lows, and for dealing with my peculiarities.
I want to thank my beloved fiancé Brea Jewell. I never imagined that I would meet the
love of my life right down the hall. Thank you for always believing in me and for always
grounding me. Thank you for always being a source of joy and laughter. You have shown me

vii

that there is more to life than just lab and soccer. Thank you for all the countless things you do
for me daily. Most of all, thank you for always being there for me. I look forward to our many
years ahead.
Lastly, I want to thank all the mentors I have had and my thesis committee. I would not
be here today without the scientific mentorship from these individuals. I want to thank my uncle,
Dr. Yao-wen Huang, for giving me my first foray into the lab. Thank you for teaching me about
the scientific method and allowing me to conduct my first scientific experiment. Thank you for
supporting me throughout this entire PhD process. I want to thank the Young Scholars Program
at the University of Georgia for giving me the opportunity to continue my scientific curiosities
while in high school. I thank Drs. Steven Stice and Amy Batal for providing an encouraging
environment for a young scientist to grow. I want to thank Dr. James Huettner for the
opportunity to work in his lab while in college. Thank you for allowing me to pursue my
interests and teaching me along the way. The experience I gained in your lab has been
instrumental while in graduate school. I want to thank Dr. Jonathan Cooper and Hemanth
Nelvagal for their collaboration, hard work, and help with our mutual work. Finally, I want to
thank my thesis committee members for their insight and support over these last four years.

viii

Abstract of the Dissertation
Infantile Batten Disease: Effective Therapy and Novel Model
by
Charles Shyng
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2016
Mark S. Sands, Chairperson

Infantile neuronal ceroid lipofuscinosis (INCL, Infantile Batten) is typically an early
onset, neurodegenerative lysosomal storage disorder. INCL is caused by mutations to the gene
CLN1 which codes for the lysosomal enzyme palmitoyl-protein thioesterase-1 (PPT1). PPT1 is a
soluble lysosomal enzyme that functions to cleave fatty acyl chains from proteins destined for
degradation. Deficiency in PPT1 leads to the accumulation of autofluorescent storage material, a
hallmark of the NCLs. The storage material has been implicated in progressive histopathological
changes in the brain such as neuronal loss, astrocytosis, microgliosis, and immune cell
infiltration. These histopathological changes result in a progression of clinical signs including
vision loss, decline in motor function, cognitive deficits, seizures, and premature death.
Currently, there are no cures or treatments for INCL. However, a murine model of INCL has
been used in pre-clinical therapy studies. The PPT1-/- mouse has been shown to be a reliable
model for the human INCL disease. Detailed temporal and spatial histopathological
examinations of murine INCL in the brain have led to intracranial gene therapy studies. These
pre-clinical studies have resulted in significant improvements in biochemical, histopathological,
and functional deficits seen in the untreated PPT1-/- mouse. However, there have only been
ix

modest improvements in lifespan. Given the identification and development of improved gene
therapy vectors, this was a surprising finding. Therefore, the first section of the dissertation, we
pursued a more thorough characterization of the central nervous system to identify potential
regions of disease not targeted by intracranial gene therapy. We identified the spinal cord as a
significant site of disease that was not previously characterized or corrected. This allowed us to
target both the brain and spinal cord with AAV-based gene therapy. We demonstrated that
targeting the entirety of the central nervous system was necessary to treat INCL more effectively.
From these and historical studies, we identified a multitude of cell types that are involved
with INCL pathogenesis. In the central nervous system, INCL has been shown to progress
sequentially from astrocytosis, to neuronal loss, to microgliosis and immune cell infiltration.
PPT1 is ubiquitously expressed; therefore, its deficiency in INCL could lead to pathology in
every cell type. Currently, we are unable to model cellular and metabolic changes in specific cell
types in INCL due to ‘cross-correction’. While ‘cross-correction’ is beneficial for the
development of therapeutics, it interferes with our ability to understand the role of PPT1 in
specific cell types. Therefore, in the second section of the dissertation, we sought to determine
the cell-autonomous nature of PPT1. Because PPT1 is a soluble lysosomal hydrolase that can
undergo ‘cross-correction’, we developed a chimeric enzyme whereby PPT1 is tethered to the
lysosomal membrane. We demonstrated that tethered PPT1 retains its enzymatic function and
does not ‘cross-correct’ in vitro and in vivo. We further demonstrated that near-ubiquitous
expression of tethered PPT1 could prevent INCL. This lays the groundwork for future studies
designed to determine the role of specific cell types in the pathogenesis of INCL.

x

Chapter 1: Introduction
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Lysosomal Storage Diseases
Lysosomal storage diseases (LSDs) are a group of rare, inherited metabolic disorders that
include over 45 different diseases (Boustany, 2013; Cox & Cachon-Gonzalez, 2012; Hers, 1965;
Neufeld, 1991; Schultz et al, 2011). LSDs occur with an incidence of approximately one in 8000
live births, making them one of the most common childhood genetic diseases (Fuller et al, 2006;
Schultz et al, 2011). Each LSD is due to mutations to a single gene and occurs mostly with an
autosomal recessive inheritance pattern (Neufeld, 1991). These mutations lead to deficiency or
reduction in function of proteins involved in the lysosomal pathway. Functional loss or reduction
of a lysosomal protein ultimately results in the accumulation of storage material either in the
lysosome or extra-lysosomal. These deficiencies have been shown to cause an increase in
lysosome proliferation and secondary effects on cellular metabolism (Vitner et al, 2010). The
storage materials have been implicated in the pathogenesis of the clinical disease; however,
precise studies to determine their role in pathology have not been performed.
Lysosomal enzymes are ubiquitously expressed and their deficiency affects multiple cell
types and organ systems. Their deficiency leads to a complex clinical presentation. Many LSDs
present with clinical signs of organomegally, skeletal deformities, cardiac abnormalities, and/or
immunologic deficiencies (Madhavarao et al, 2009). Interestingly, approximately two-thirds of
all LSDs present with a neurological phenotype (Jardim et al, 2010). Those disorders that present
with neurological dysfunction exhibit behavioral problems, regression in cognition, loss of visual
acuity and hearing, verbal deterioration, and/or loss of motor function. Patients are typically
diagnosed after disease onset which can range from early infancy to adulthood (Platt &
Lachmann, 2009). Interestingly, the mutated gene does not necessarily determine the age of
onset (Maire, 2001). It has been shown that these mutations lead to a variable scale of lysosomal
2

enzyme activity, which ultimately influences the progression of the disease. This most likely is
caused by the presence of yet unknown modifying genes. Ultimately, patients suffer an early
death after an undefined period of cognitive or behavioral regression. Currently, there are no
comprehensive treatments for lysosomal storage disorders. However, there has been progress
towards the development of effective therapies involving gene and cell therapy as well as the
development of small molecule drugs and recombinant enzyme (Parenti et al, 2015).

Neuronal Ceroid Lipofuscinoses
The Neuronal Ceroid Lipofuscinoses (Batten Disease, NCL) are a group of mostly
pediatric neurodegenerative diseases (Goebel & Wisniewski, 2004). The incidence of Batten
disease is ~1 in 12,500 live births making it the most common inherited pediatric neurologic
disorder. This subgroup of lysosomal storage disorders are grouped together due to their
common histologic hallmark of autofluorescent storage material (AFSM) accumulation (Mole &
Williams, 1993). There is a variety of forms of Batten disease which have been historically
classified based on age of onset (Dyken, 1989). However, in recent years, it has been determined
that age of onset and the mutated gene are not necessarily correlated (Wisniewski et al, 2001).
Presently, the various forms of Batten disease are classified based on the mutated gene. Currently
there are over 14 different genes associated with NCL (Anderson et al, 2013). The progression of
histopathogenesis in the brain has been well documented among the NCL variants (Bennett &
Rakheja, 2013). The similarities in disease progression include neuronal loss, retinal
deterioration, cortical thinning, brain atrophy, and neuroinflammation. The accumulation of
AFSM is present in all variants, though the identification of AFSM substrates and whether
AFSM is pathogenic has not been elucidated (Palmer et al, 2013). It has also been recently
3

shown in patients and murine models that NCL variants have metabolic and cardiac
abnormalities (Galvin et al, 2008; Ostergaard et al, 2011; Woloszynek et al, 2007). Since the
NCL field had largely focused on disease associated with the brain, these recent discoveries have
led to studies focusing on systemic disease. Most studies have been directed to study the brain,
while the spinal cord (central nervous system), the peripheral nervous system (PNS), and the
autonomic nervous system (ANS) have been largely overlooked.

Infantile Neuronal Ceroid Lipofuscinosis
The infantile form of NCL is one of the earliest onset and most aggressive forms of
Batten disease. Infantile NCL (INCL) was first described in 1973 by Haltia et al and
subsequently referred to as Santavuori-Haltia disease (Haltia et al, 1973b; Santavuori et al,
1973). While most cases of INCL were located in the Scandinavian region, with the
improvement in genomic techniques, INCL has been described worldwide with ages ranging
from infancy to adulthood (Hofmann et al, 2001b; Kousi et al, 2012). Children with INCL are
pre-symptomatic at birth but begin exhibiting psychomotor retardation between 6-12 months.
Developmental regression begins first with loss of motor and visual functions followed by
cognitive decline. As the disease progresses, patients become blind and ataxic, eventually losing
complete muscle coordination and tone. Patients also develop myoclonic seizures. Near end of
life, patients are wheelchair bound and are often on feeding tubes and ventilation (Jadav et al,
2014; Santavuori et al, 1974; Santavuori et al, 1973; Simonati et al, 2009). Currently, there are
no effective treatments for INCL.
Mutations leading to INCL were identified in the CLN1 gene in 1991 (Schonherr et al,
1991). Since then, over 61 novel mutations have been identified in the CLN1 gene (Kousi et al,
4

2012). They consist of missense, nonsense, splicing affected, insertions, deletions, or a
combination of mutations. These mutations lead to reduced enzymatic activity of PPT1. The
enzymatic deficiency leading to INCL was not discovered until 1995 (Vesa et al, 1995). The
authors showed that palmitoyl-protein thioesterase-1 (PPT1), a soluble lysosomal hydrolase, was
deficient in INCL patients. A follow-up study showed that replacement of PPT1 via recombinant
enzyme was able to correct the disease in in vitro lymphoblast cultures (Camp & Hofmann,
1993; Camp et al, 1994; Hellsten et al, 1996; Hofmann et al, 2001a; Verkruyse & Hofmann,
1996; Verkruyse et al, 1997). PPT1 functions to cleave fatty acyl groups from modified cysteine
residues in proteins destined for degradation. It is ubiquitously expressed and has been shown to
be developmentally and spatially regulated (Isosomppi et al, 1999). Recently, PPT1 has been
shown to co-localize with synaptic vesicles and synaptosomes in neurons, however, the reason
has yet to be discovered (Kim et al, 2008; Lehtovirta et al, 2001). Deficiency in PPT1 leads to
the biochemical, histological, and behavioral changes associated with INCL.
The cellular pathology in PPT1 deficiency has the hallmark of NCLs, autofluorescent
storage material. The ultrastructural appearance of storage material has been described as
granular osmiophilic deposits (GRODs) (Goebel et al, 1995; Siegismund et al, 1982). These
deposits are localized to the lysosome and their complete composition has yet to be determined.
However, it has been shown in the brain to contain a complex mixture of protein and lipids with
major products of saposin A and D and glial fibrillary acidic protein (GFAP) (Tyynela et al,
1993).
Analyses of the INCL brain show gross anatomical changes. There is severe brain
atrophy such that the mass of the INCL brain is only 50% of an age-matched normal child
(Haltia et al, 1973a). There is dramatic thinning of the cortical layers. The accumulation of
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lipopigments has been found ubiquitously, however, the extent of their accumulation varies.
They are prevalent in the brain, reticuloendothelial system, intestine, bone marrow, and Kupffer
cells (Siegismund et al, 1982). Using magnetic resonance imaging, atrophy was seen in the
thalamus and basal ganglia by T2 hypointensity as well as in the cerebral cortex (Jadav et al,
2014; Jadav et al, 2012; Santavuori et al, 1992; Vanhanen et al, 1995a). This was correlated with
loss of cortical neurons as well as loss of axons and myelin sheaths (Vanhanen et al, 1995a;
Vanhanen et al, 1995b). There is also atrophy of the retinal pigment epithelial cells and
accumulation of GRODs ultimately leading to loss of an electroretinography (ERG) signal
(Vanhanen et al, 1997; Weleber et al, 2004)

The murine INCL model
A mouse model of INCL was created in 2001 that is deficient in PPT1 activity (PPT1-/-)
(Gupta et al, 2001). This model had a neomycin cassette inserted into exon 9 of the murine PPT1
gene via homologous recombination. This mutation introduced a premature stop codon as well as
abolished two of the amino acids involved in the catalytic triad. Characterization of the mouse
model has been extensive with much of the studies focused on the brain (Dearborn et al, 2015;
Galvin et al, 2008; Gupta et al, 2001; Kielar et al, 2007; Macauley et al, 2009). The PPT1-/mouse has a median lifespan of 8.5 months and accumulations AFSM ubiquitously (Gupta et al,
2001). Similar to the human disease, there is widespread neurodegeneration and
neuroinflammation (Kielar et al, 2007; Macauley et al, 2009). Temporal studies have shown that
astrocytosis, detectable at 3 months, precedes neurodegeneration, detectable at 5 months.
Microgliosis and infiltrating immune cells are detectable at 7 months. Overall, there is brain
atrophy and cortical thinning, with brain weights of PPT1-/- mice at a terminal time point
6

approximately 60% that of normal age-matched animals (Bible et al, 2004). There are significant
decreases in retinal function measured by ERG and motor dysfunction measured by rotarod
beginning at 4 months and 5 months, respectively (Griffey et al, 2005; Griffey et al, 2006).
While mice have been shown to have decreased ERGs, they maintain some visual acuity in the
early stages of disease (Dearborn et al, 2015; Griffey et al, 2005). Motor function continues to
decrease over time and PPT1-/- mice are unable to stay on the rotarod past 7 months.
Spontaneous seizure activity begins at 7 months in 50% of tested animals and occurs in 100% of
PPT1-/- animals at 7.5 months (Bible et al, 2004).
While INCL studies have primarily focused on the brain, studies have shown histological
and pathological defects systemically. Autofluorescent material has been shown to accumulate in
most tissues outside of the brain, with prevalence in the kidney and spleen (Galvin et al, 2008).
AFSM has been seen in the liver, bone, eye, and heart. Cardiac defects have been reported in the
PPT1-/- mouse (Galvin et al, 2008). Echocardiography revealed left ventricular hypertrophy and
aortic dilatation. It has also been shown that PPT1-/- mice have metabolic dysfunction
(Woloszynek et al, 2007). Although PPT1-/- mice have relatively normal plasma chemistry, they
have decreased body weights compared to wild-type mice and have significantly decreased
adiposity. PPT1-/- mice lose 25% of adiposity and have decreased leptin levels as compared to
wild-type mice. However, PPT1-/- mice consume more food than wild-type mice and have a
slower metabolic rate. This suggests that PPT1 deficiency leads to altered energy utilization
similar to that seen in other LSDs (Woloszynek et al, 2007; Woloszynek et al, 2009). Overall, the
PPT1-/- mouse recapitulates most of the features of human INCL and is useful as a model for
pre-clinical therapy studies.

7

INCL Therapy
Small molecule drugs
A number of small molecule drugs have been used to treat human and murine INCL by
targeting the primary genetic defect through PPT1 mimetics or by targeting the secondary
disease mechanisms. Two PPT1 mimetics have been developed for pre-clinical studies. The
development of phosphocysteamine as a small molecule drug for INCL was utilized because it
functions similarly to PPT1. Phosphocysteamine was shown in vitro to lysosomotrophic and is
capable of disrupting thioester linkages. The in vitro study of phosphocysteamine showed
depletion of lysosomal ceroids (GRODs) and showed a decrease in saposin A and D which have
been shown to accumulate in GRODs (Zhang et al, 2001). This in vitro study prompted the use
of phosphocysteamine in the PPT1-/- mouse model. Unfortunately, delivery of
phosphocysteamine showed no improvement of biochemical, histological, or functional
parameters of INCL (Roberts et al, 2012). Despite this, a clinical trial was conducted combining
cysteamine bitartrate with N-acetylcysteine (Zhang et al, 2001). The children showed minimal
improvement in clinical signs of disease as measured by EEG and MRI (Levin et al, 2014).
Another PPT1 mimetic, N-tert-butyl-hydroxlamine (NtBuHA), has recently been
developed. NtBuHA has been shown to similarly deplete lysosomal ceroid accumulation in vitro.
NtBuHA was shown to cross the blood-brain barrier and minimally improve histological and
clinical signs of disease in the PPT1-/- mouse (Sarkar et al, 2013). This PPT1 mimetic has not
yet been tested in clinical trials.
Other small molecule drugs have been tested in pre-clinical studies on INCL mice or
patient fibroblasts. In one study, a stop-codon read-through drug PTC124 was utilized in vitro.
PPT1 nonsense mutations are one of the most prevalent mutations. PTC124 showed an increase
8

in PPT1 activity and decreased GRODs (Sarkar et al, 2011). In another study, the secondary
mechanism of disease, neuroinflammation, was targeted using Minozac. Minozac is a small
molecule inhibitor of proinflammatory cytokines in the brain. This small molecule has been
shown to attenuate neuronal loss and prevent behavioral deficits in other models of neurologic
disease (Hu et al, 2007). Given the upregulation of proinflammatory cytokines in INCL, Minozac
was used in a pre-clinical experiment. Treatment with Minozac resulted in decreased seizures,
however, it did not improve other clinical parameters (Macauley et al, 2014). There were slight
improvements in histology with slight decreases in GFAP and CD68 staining, which are markers
of neuroinflammation. Similarly, there were subtle decreases in cytokine upregulation.

Cross-correction
The process of ‘cross-correction’ is the basis for several therapeutic strategies to treat
soluble lysosomal enzyme deficiencies. It was first proposed by de Duve in 1964 as a treatment
strategy, and has been refined since its actual discovery in the late 1960s (Deduve, 1964). ‘Crosscorrection’ was a fortuitous discovery by Elizabeth Neufeld and colleagues in 1968 (Fratantoni
et al, 1968). Discoveries about lysosomal enzymes and their trafficking soon followed detailing
the mannose-6-phosphate receptor pathway and the modifications of oligosaccharides on
lysosomal enzymes to mediate lysosomal targeting (Dahms et al, 1989; Kornfeld et al, 1982;
Natowicz et al, 1979; Varki & Kornfeld, 1980). Briefly, mannose-6-phosphate (M6P) groups are
attached post-translationally to proteins destined for the lysosome. Via this modification,
enzymes bind to the M6P/Insulin-growth factor II (M6P/IGFII) receptor in the Golgi and are
transported through the endosomal pathway. Detachment of the modified proteins in the
acidified lysosome allows the M6Pr/IGFIIr to recycle to the Golgi or to the plasma membrane
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(Dahms et al, 1989). Through an undetermined process, possibly exosomes, a small percentage
of lysosomal enzymes are secreted into the extracellular space. These soluble enzymes can be
retrieved by neighboring cells through the mannose-6-phosphate or mannose receptor-mediated
uptake pathways. The endocytosed enzymes are then trafficked back to the lysosome where they
participate in normal cellular functions (Sands & Davidson, 2006). ‘Cross-correction’ is the
process underlying stem-cell transplantation, enzyme replacement therapy, and gene replacement
therapy. Stem-cell transplantation and enzyme replacement therapy have become standard of
care for a growing number of LSDs.

Cell-mediated Therapy
Cell-mediated therapy has been suggested to treat INCL. It is suggested that a limited
number of engrafted cells are necessary to treat the disease by taking advantage of ‘crosscorrection’. Two methods have been performed pre-clinically, to date. Neural stem cells have
been transplanted in INCL mice and this procedure has progressed to a phase one clinical trial.
Neural stem cell transplantation provided increased PPT1 activity, decreased AFSM, and
delayed motor dysfunction in the mouse (Tamaki et al, 2009). However, the overall effect on
lifespan was not examined. A clinical trial was initiated in 2005 (Taupin, 2006); however, the
clinical trial was withdrawn prior to enrollment of patients (NCT01238315).
Bone marrow transplantation (BMT) was utilized in a pre-clinical study for INCL. BMT
has been shown to play a dual role in lysosomal storage diseases of ‘cross-correction’ and
immunomodulation. In other LSD models, BMT results in varying degrees of efficacy
(Birkenmeier et al, 1991; Qin et al, 2012; Reddy et al, 2011; Sands et al, 1993), and has become
standard of care in certain patient populations. In INCL, BMT was shown to have a detrimental
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effect. INCL mice treated with BMT had a decreased lifespan and impaired motor function
(Macauley et al, 2012).
Enzyme replacement therapy
Enzyme replacement therapy (ERT) has been shown to be one of the more promising
candidates for INCL therapy. Similar to cell-mediated approaches, ERT takes advantage of
‘cross-correction’. Recombinant PPT1 delivered intravenously has been shown to correct the
systemic histologic phenotype in INCL mice and improve motor function and longevity (Hu et
al, 2012; Lu et al, 2010). Intrathecal injections of rPPT1 were attempted in PPT1-/- mice to
target the brain pathology. This study showed that intrathecal injections of rPPT1 were able to
partially correct histological hallmarks of INCL in the brain, extend lifespan, and improve motor
function (Lu et al, 2015). However, the improvements observed in both studies were minor and
rPPT1 had to be administered on a regular basis.
Gene Therapy Studies
Gene therapy was first proposed by Friedmann & Roblin in 1972 as a technique to treat
human genetic diseases (Friedmann & Roblin, 1972). Since then, a number of pre-clinical gene
transfer studies have been performed with a variety of viral vectors (e.g. lentivirus, adenoassociated virus, adenovirus). In the PPT1-/- mouse, gene therapy experiments have been
performed primarily using adeno-associated viral (AAV) vectors targeting the forebrain,
hippocampus, and cerebellum. Progressive biochemical, histological, and behavioral
improvements have been observed as newer generation vectors have been developed. A firstgeneration AAV2 vector was utilized to supply a persistent source of PPT1 to the PPT1-/- brain
via intracranial injections (Griffey et al, 2004). The vector was able to provide localized
enzymatic activity sufficient to correct the biochemistry and histopathology in the area near the
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injection site. However, the correction was limited by the diffusion of the AAV2 viral vector and
‘cross-corrective’ enzyme. An increased dose of the AAV2 vector was able to further improve
biochemistry, histopathology, and behavior, but the lifespan of the treated mice was not
significantly extended compared to the untreated PPT1-/- mice (Griffey et al, 2006). In
subsequent studies, the second-generation AAV2/5 vector was utilized. The intracranial
AAV2/5-treated mice had greater biochemical, histopathological, and behavioral improvements
compared to AAV2. Importantly, there was also a significant extension in lifespan (Macauley et
al, 2012; Macauley et al, 2014; Roberts et al, 2012). This may be explained by the greater
transduction efficiency and distribution of the AAV2/5 vector in the brain (Burger et al, 2004).
While the improvements have been significant compared to PPT1-/- mice, overall, they have
been modest compared to wild-type. Gene therapy has been shown in pre-clinical studies of
INCL to be the most effective approach to date. A third-generation vector, AAV2/9, has been
shown to have a broader distribution in the CNS of animal models and may increase therapeutic
efficacy in INCL (Dayton et al, 2012; Schuster et al, 2014; Swain et al, 2014).

Goals of the Thesis
Spinal Cord pathology
CNS-directed gene therapy was shown to have only modest improvements in lifespan and
motor function. This was surprising given the nearly normal levels of PPT1 activity in the brain.
Thus, it was hypothesized that there were regions of the central nervous system that were not
targeted by brain-directed gene therapy. Therefore, we conducted a more thorough retrospective
analysis of the AAV2/9- and AAV2/5-treated central nervous system to determine the extent of
CNS correction. In the retrospective analysis from the treated animals, there was an increase in
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markers for astrocytosis and neuroinflammation in the spinal cords. A comprehensive temporal
and spatial analysis of the PPT1-/- spinal cord was conducted in collaboration with Dr. Jonathan
Cooper, King’s College.
The retrospective analysis of PPT1-/- animals treated with gene therapy showed that there
was the accumulation of AFSM throughout the spinal cord and brain stem similar to the PPT1-/brain. Furthermore, there was an increase in GFAP and CD68 staining, which are markers for
neuroinflammation. The inability of intracranial injections of AAV2/9 to treat the brainstem and
spinal cord effectively revealed a potential new target for a combinatorial AAV gene therapybased approach. Therefore, the first goal of this study was to perform a comprehensive analysis
of the central nervous system of treated animals to determine the extent of spinal cord disease not
treated via intracranial AAV vector delivery. The second goal of this study was to determine
whether targeting both the brain and the spinal cord in PPT1-/- mice would significantly improve
efficacy. In this study, we transitioned from the second-generation AAV vector (AAV2/5hPPT1) to the third-generation AAV vector (AAV2/9-hPPT1) to determine whether a third
generation vector would provide significantly increased efficacy. We hypothesized that AAVbased intracranial and intrathecal injection of AAV2/9-hPPT1 would significantly extend the
lifespan of PPT1-/- mice and improve both clinical and pathological parameters compared to
either treatment alone.

Multiple cell types involved in INCL pathogenesis
Multiple studies of INCL neuropathology have shown that there are many CNS cell types
affected by PPT1 deficiency. Murine INCL progresses sequentially from astrocytosis, to
neuronal loss, and to microgliosis and immune cell infiltration. This progression has been
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documented throughout the central nervous system and has been shown to have a profound
impact on the severity of the disease. When reactive astrocytosis is inhibited by preventing the
upregulation of intermediate filaments (conducive to astrocyte transition from dormant to
reactive), the progression of INCL is accelerated. PPT1-/- mice deficient in intermediate
filaments have a shortened lifespan and an increase in neuroinflammatory markers. Macauley et
al, (2011) showed that reactive astrocytosis might play a neuroprotective role in INCL
pathogenesis (Macauley et al, 2011; Shyng & Sands, 2014). Neuronal loss and cortical thinning
have been well documented in INCL, and their loss is both temporal and spatial. Studies have
shown that neuronal loss first begins in the thalamus followed by neurodegeneration in the cortex
and cerebellum (Kielar et al, 2007; Macauley et al, 2009). It has been shown that a subset of
neuronal proteins which are involved in the regulation of axonal and synaptic vulnerability are
altered in INCL. Neuronal protein expression changes were present prior to synaptic or axonal
morphological alterations and followed a similar spatial progression (Kielar et al, 2009). There
are also changes to receptors and channels involved with neuronal function associated with PPT1
deficiency (Aby et al, 2013; Kim et al, 2008; Qiao et al, 2007; Tikka et al, 2016; Virmani et al,
2005; Zhang et al, 2006). Furthermore, PPT1 deficiency has been shown to be involved in bloodbrain barrier maintenance, neuroinflammation, and systemic metabolic and cardiac dysfunction
(Galvin et al, 2008; Khaibullina et al, 2012; Saha et al, 2008; Saha et al, 2012; Tikka et al, 2016;
Wei et al, 2011; Woloszynek et al, 2007). While studies have yet to show that PPT1 deficiency
directly influences myelination, preliminary studies have shown changes in the level and
organization of myelin (Macauley et al, 2009).
Overall, this suggests that multiples cell types are involved in INCL disease. This may
not be surprising since PPT1 is ubiquitously expressed. Unfortunately, our ability to model

14

cellular and metabolic changes in specific cell types in lysosomal storage diseases has been
lacking. This is due primarily to ‘cross-correction’. It is beneficial to our understanding of INCL
as well as the development of therapeutics to understand the role of PPT1 in specific cell types.
This will ultimately guide therapeutic strategies in determining the necessity of correcting all cell
types or a specific subset of cell types in order to prevent disease.

Tethered PPT1 to the lysosomal membrane
To understand the cell autonomous roles of specific cell types in INCL, we engineered a
chimeric lysosomal membrane tethered form of PPT1 using the transmembrane domain/signaling
peptide of lysosomal-associated membrane protein-1 (LAMP1). The transmembrane
domain/signaling peptide has been shown to be necessary and sufficient for lysosomal targeting
of LAMP1, and may be used as a targeting and retention mechanism for soluble lysosomal
hydrolases (Guarnieri et al, 1993; Marathe et al, 2000). Therefore, the second major goal of this
thesis was to tether PPT1 to the lysosomal membrane through the transmembrane portion of
LAMP1 in order to understand the cell autonomous nature of INCL by taking advantage of the
Cre-loxP system. Therefore, we inserted a loxP-STOP-loxP sequence into the chimeric PPT1LAMP1 transgene to achieve cell specificity. The loxP-STOP-loxP region would prevent both
transcription and translation of our chimeric lysosomal enzyme unless in the presence of Cre
recombinase. Unfortunately, the transgene appeared to be unstable leading to constitutive and
ubiquitous expression of PPT1-LAMP1 and an inability to respond to Cre recombinase.
However, we showed that membrane tethered PPT1 retained enzyme activity and was capable of
preventing the biochemical, histological, and behavioral phenotype of INCL when expressed
ubiquitously. Therefore, this study demonstrates a proof-of-principle that tethering PPT1 to the
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lysosomal membrane could be a viable approach to address questions regarding the role of
various cell types in the progression of INCL once cell-specific expression can be achieved.
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Chapter 2: A new and effective therapeutic
target for Infantile Batten disease

This chapter is adapted from the following manuscripts:
Nelvagal H, Shyng C, Dearborn JT, Sands MS, Cooper JD. Onset and progression of spinal cord
pathology in a murine model of INCL. In Preparation.
Shyng C, Nelvagal H, Dearborn JT, Cooper JD, Sands MS. A new and effective therapeutic
target for Infantile Batten disease. In Preparation.
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Introduction
The neuronal ceroid lipofuscinoses (Batten disease, NCL) are a group of inherited
pediatric neurodegenerative lysosomal storage disorders (Geraets et al, 2016; Mole & Williams,
1993). Infantile Batten disease is the most rapidly progressing form of NCL and is caused by
mutations in the CLN1 gene that codes for palmitoyl-protein thioeseterase-1 (PPT1), a soluble
lysosomal hydrolase (Kousi et al, 2012; Vesa et al, 1995). PPT1 cleaves fatty acyl chains from
proteins undergoing lysosomal degradation. Deficiency in PPT1 leads to the pathological
hallmarks of NCL, which include the accumulation of autofluorescent storage material (AFSM),
neurodegeneration, and glial activation (Goebel et al, 1995; Haltia et al, 1973a; Haltia et al,
1973b; Hellsten et al, 1997; Hellsten et al, 1996; Jokiaho et al, 1990; Santavuori et al, 1973;
Santavuori et al, 1992; Schriner et al, 1996; Syvanen et al, 1997; Vanhanen et al, 1995a;
Vanhanen et al, 1995b; Vanhanen et al, 1997; Vesa et al, 1995). Though patients are typically
asymptomatic at birth, by 6 months, INCL patients exhibit progressive degenerative clinical
signs in vision, motor function, and cognition, which ultimately lead to a shortened lifespan
(Goebel & Wisniewski, 2004; Haltia et al, 1973a; Haltia et al, 1973b; Santavuori et al, 1973;
Vanhanen et al, 1995a; Vanhanen et al, 1995b; Vanhanen et al, 1997). Currently, there are no
effective treatments or cures available for INCL.
The PPT1-deficient (PPT1-/-) mouse shares most of the biochemical, pathological, and
clinical signs of human INCL (Gupta et al, 2001). Histopathological characterization of the
disease in the forebrain and the cerebellum demonstrated progressive AFSM accumulation,
neurodegeneration, astrocytosis, and neuroinflammation (Bible et al, 2004; Gupta et al, 2001;
Kielar et al, 2007; Macauley et al, 2009). There is overall brain atrophy with extensive cortical
thinning concurrent with astrocyte and microglial activation. At a terminal time point, the mass
of the murine brain is decreased by over 20 percent (Bible et al, 2004). The murine model has
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functional deficits including, but not limited to retinal dysfunction, loss of motor coordination,
seizure activity, cardiac insufficiency, and metabolic imbalances (Galvin et al, 2008; Griffey et
al, 2005; Kielar et al, 2007; Macauley et al, 2009; Woloszynek et al, 2007). PPT1-/- mice
ultimately have a shortened lifespan with a median lifespan of 8.4 months.
There have been several pre-clinical therapy studies performed in the PPT1-/- mouse.
Small molecule drugs that act as PPT1 mimetics such as N-tert-butyl hydroxylamine and
Cystagon have resulted in minimal improvements (Levin et al, 2014; Sarkar et al, 2013; Zhang et
al, 2001). Enzyme replacement therapy (ERT) through intravenous or intrathecal routes of
administration resulted in minor clinical improvements (Levin et al, 2014; Sarkar et al, 2013;
Zhang et al, 2001). However, the improvements in PPT1-/- neuropathology is only observed
when treatment is provided at an early stage (i.e. before the establishment of the blood-brain
barrier) (Hu et al, 2012). To date, the most promising treatment in PPT1-/- mice has been CNSdirected gene therapy either alone or combined with other approaches (Griffey et al, 2004;
Griffey et al, 2006; Macauley et al, 2012; Macauley et al, 2014; Roberts et al, 2012).
Pre-clinical gene therapy experiments have been performed using adeno-associated viral
(AAV) vectors targeting the forebrain, hippocampus, and cerebellum. Progressive biochemical,
histological, and behavioral improvements have been observed as newer generation vectors have
been developed. First generation AAV2 vectors resulted in improvement in biochemical and
histological pathology in the regions targeted. However, functional improvement was not
observed until multiple sites of disease within the INCL brain were targeted by AAV2-hPPT1
(Griffey et al, 2004; Griffey et al, 2006). Overall, AAV2-hPPT1 increased PPT1 activity,
reduced AFSM accumulation, and improved histological markers of disease, but did not
significantly extend the lifespan. The second-generation AAV2/5 vector was shown to have
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improved neural transduction and distribution in the murine brain (Burger et al, 2004). Besides a
normalization of PPT1 activity, utilization of AAV2/5-PPT1 showed marked reduction in AFSM
and pathology, as well as an extension in median lifespan by approximately two months
(Macauley et al, 2012; Macauley et al, 2014; Roberts et al, 2012). The clinical improvements
have been modest potentially due to limited distribution of the AAV vector (Aschauer et al,
2013; Gray et al, 2013).
A third generation vector, AAV2/9, has been shown to have a broader distribution in the
CNS in several animal models (Dayton et al, 2012; Schuster et al, 2014; Swain et al, 2014).
Therefore, in the current study, the AAV2/5-hPPT1 vector used in previous pre-clinical INCL
gene therapy studies was transitioned to AAV2/9-hPPT1.
We show that intracranial injection of AAV2/9-hPPT1 provides significantly greater
efficacy compared to AAV2/5-hPPT1. However, the lifespan was still significantly less than
wildtype animals despite having nearly normal PPT1 levels in the brain. Therefore, we
performed a more thorough histological analysis of the central nervous system of treated
animals. This analysis revealed significant disease throughout the spinal cord that was not
corrected by intracranial AAV vector delivery. These findings suggested that spinal cord
pathology could play a significant role in INCL pathogenesis. In collaboration with Hemanth
Nelvagal and Jonathan Cooper (King’s College, London), we performed a comprehensive
temporal and spatial analysis of the spinal cord in INCL mice. A brief summary of the findings
from this study will be presented in this Chapter. These data taken together revealed a new
region of disease and a possible therapeutic target. Therefore, we targeted the spinal cord with
intrathecal gene therapy to determine whether AAV-based gene therapy could ameliorate INCL
pathogenesis. Furthermore, we hypothesized that intracranial plus intrathecal injections of
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AAV2/9-hPPT1 would significantly extend the lifespan of PPT1-/- mice and improve both
clinical and pathological parameters compared to either treatment alone.
Intracranial injection of AAV2/9-hPPT1 resulted in greater therapeutic efficacy than
intrathecal injection, although both provide significant biochemical, histological, and behavioral
improvements compared to untreated PPT1-/- mice. Simultaneous treatment of both the brain
and spinal cord resulted in the greatest efficacy. In fact, targeting these two regions resulted in
synergistic improvements in lifespan and motor function. These data suggest that the spinal cord
disease plays a major role in the overall pathogenesis of INCL. These data also identify the
spinal cord as an important therapeutic target.

Material and Methods
PPT1-/- and WT mice
PPT1-/- mice were created by Gupta et al, (2001). Both congenic PPT1-/- and wild-type
(WT) mice were maintained on a C57Bl/6J background at Washington University School of
Medicine by MSS. The colonies were maintained separately through homozygous mating. The
Thy1-YFP PPT1-/- mouse model was generated by crossing the Thy1-YFP reporter mouse (Feng
et al, 2000)(Tg(Thy1-YFP)16Jrs, The Jackson Lab, Bar Harbor, ME) to the PPT1-/- mouse. The
reporter mice were maintained as Thy1-YFP+/-, PPT1-/-. All procedures were performed in
accordance with a protocol approved by the IACUC at Washington University School of
Medicine.

Recombinant AAV production
The rAAV2/9-hPPT1 vector used in this study was packaged at the University of North
Carolina Vector Core. Briefly, the vector contained the CAGGS promoter, human PPT1 cDNA,
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and a rabbit B-globin polyadenylation signal all flanked by the AAV2 inverted terminal repeats
(Griffey et al, 2004). Viral titers were 1x1012 vg/ml for all injections.

Intracranial and Intrathecal injections
On postnatal day 1 (PND1) or PND2 PPT1-/- pups received intracranial or intrathecal
injections with AAV2/9-hPPT1 or AAV2/5-hPPT1 (1x1012 vg/ml) using a Hamilton syringe and
a 30-gauge needle. For intracranial injections, two microliters of virus were injected bilaterally
into the anterior cortex, hippocampus, and cerebellum as previously described (Griffey et al,
2006). For intrathecal injections, P1 or P2 PPT1-/- pups were injected in the lumbar region as
previously described (Elliger et al, 1999; Hawkins-Salsbury et al, 2015). Briefly, 15 microliters
of virus was mixed with three microliters of sterile Trypan-blue. Fifteen microliters of the
mixture was injected. A successful injection was confirmed by the appearance of Trypan-blue in
the tail and the cerebellum. For the combination treatment, both intracranial and intrathecal
injections were performed on the same day in the same pup.

Treatment Groups
For the initial AAV2/5 vs AAV2/9 comparison, four groups were generated with 10 mice
per group: 1) PPT1-/- mice, 2) AAV2/5-hPPT1 intracranial injected PPT1-/- mice (IC-AAV2/5),
3) AAV2/9-hPPT1-/- intracranial injected PPT1-/- mice (IC-AAV2/9), and 4) wildtype (WT)
mice. For the combination study, five treatment groups were generated consisting of 22 mice per
group: 1) PPT1-/- mice, 2) IC-AAV2/9, 3) AAV2/9-hPPT1 intrathecal injected PPT1-/- mice
(IT-AAV2/9), 4) AAV2/9-hPPT1 intracranial and intrathecal injected PPT1-/- mice (IC/ITAAV2/9), and 5) WT mice. Randomly selected mice were analyzed at pre-determined time

22

points (3, 5, 7, and 9 months) for biochemical and histological analyses (n=3 mice/group).
Experimental and control animals were randomly assigned identification numbers such that the
person performing the analyses was blind to the genotype and treatment.
Lifespan
Longevity was assessed in the treatment and control groups (n=10-11 mice/group). The
lifespan was determined by death or euthanasia for humane reasons. A Kaplan-Meier lifespan
curve was used to measure survival and significant differences were determined using a log-rank
analysis (p<0.05).

Rotarod Testing
Motor function was assessed in the same treated PPT1-/- and control mice (n=10) used
for longevity using a constant-speed (3 rpm) rotarod beginning at 5 months of age, and every two
months thereafter as previously described (Dearborn et al, 2015; Griffey et al, 2006). Statistical
significance was determined using one-way ANOVA at each time point followed by a
Bonferroni post hoc test.

PPT1 activity and secondary enzyme elevations
Tissue was collected at pre-determined time points. Three mice per treatment group were
euthanized via lethal injection (Fatal Plus, Vortech Pharmaceutical, Dearborn, MI). Blood was
collected from the right ventricle using a 1ml tuberculin syringe and a 26-gauge needle and
allowed to clot for 15 minutes before centrifugation at 1000xg for 10 minutes. Serum was
collected and flash frozen. Mice were then transcardially perfused with phosphate-buffered
saline (PBS) until the liver was cleared of blood. Portions of heart, liver, spleen, kidney, and eye
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were flash frozen for subsequent biochemical analyses. Additional tissue samples were
immersion fixed in 4% paraformaldehyde (PFA) in PBS for 24-hr then cryoprotected in 30%
sucrose solution in Tris-buffered saline (TBS). The spine was removed by cutting at the axis/C1
and resecting the spine where the spine enters the tail. The spine was fixed and cryoprotected as
described above. The brain was removed, weighed, and bisected sagittally; the left hemisphere
was flash frozen while the right hemisphere is fixed and cryoprotected as described above. PPT1
assays were performed on homogenates from the brain, heart, and liver as previously described
using the 4-MU-palmitate fluorometric assay and normalized to total protein (van Diggelen et al,
1999). Secondary elevations of another lysosomal enzyme, β-glucuronidase, were determined as
previously described using 4-MU-β-D-glucuronide fluorometric assay and normalized to total
protein (Sands et al, 1994). Significance was determined using a two-way ANOVA followed by
a Bonferroni post-hoc analysis for all enzyme assays.

Thy1-YFP PPT1 spinal cord analysis
Thy1-YFP PPT1-/- and Thy1-YFP PPT1+/- mice spinal cords were isolated, fixed, and
cryoprotected as described above. Spinal cords were sectioned longitudinally at 32 micrometers
directly onto slides. Confocal images of Thy1-YFP PPT-/- and Thy1-YFP PPT1+/- spinal cords
were captured at the lumbar region at 10x magnification. Keeping all the parameters identical
from slide to slide, images were analyzed using ImageJ. Relative fluorescence units were
calculated by converting the image to a binary black and white image. The number of white
pixels were calculated and divided by the total pixel area. Three sections were analyzed per
image and averaged. A Student’s t-test was performed for significance with p<0.05.

24

Histochemical Stain
A histochemical stain for PPT1 activity was performed on sagittal brain sections as
previously described (Dearborn et al, 2016). Briefly, unfixed tissue was isolated from treated
mice and immediately embedded in Optimal Cutting Temperature Compound (OCT; Sakura
Finetek USA, Inc., Torrance, CA) on dry ice. Tissues were cryosectioned at 16 micrometers and
mounted on Superfrost Plus slides (Thermo Fisher Scientific, Waltham, MA, USA). Tissues
were fixed in 4% paraformaldehyde in PBS on the slides for 20 min at 4°C. Slides were then
rinsed and equilibrated with 0.2M sodium acetate buffer (pH 4.5). Each slide was covered with
the histochemical solution overnight at 37⁰C in a humidified chamber. Slides were rinsed with
water, counterstained with Nuclear Fast Red (Sigma-Aldrich, St. Louis, MO, USA), and
coverslipped.

Brain and Spinal Cord processing and histological analysis
Brain processing and analysis was performed as previously described (Macauley et al,
2012). Briefly, brains from treated and control mice were removed and fixed for 24 hr in 4%
PFA in PBS. They were then cryoprotected in 30% sucrose in TBS. Brains were sectioned at 40
micrometers and immunostained for GFAP and CD68, or Nissl. Spinal cords were processed as
described in Nelvagal et al, (in preparation). Briefly, spinal cords were removed from treated and
control mice, fixed for 24 hr in 4% PFA in PBS, followed by cryoprotection in 30% sucrose.
Sections were cut at 40 micrometers and stained with Cresyl Fast Violet (Nissl staining) and
immunostained for GFAP and CD68. Regional volumes were calculated as previously described
(Kuhl et al, 2013). Briefly, whole volumes and gray matter were measured in 24 sequential
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sections. Using the Cavelieri estimation, whole cord volumes and whole gray matter volumes
were estimated.

Cytokine Profile Analysis
Cytokine profiling was performed using an Affymetrix multiplex assay through the
Center for Human Immunology and Immunotherapy Programs (CHiiPS) Immunomonitoring Lab
(IML) at Washington University School of Medicine. Nine analytes (GRO-α, IFN-γ, IL-10, IP10, MCP-1, MCP-3, MIP-2, RANTES, and TNF- α) were measured in brain homogenates of
treated animals. Treated mice were perfused with PBS prior to removal of the brain. Half of the
brain was flash frozen and homogenized in 10mM Tris (pH 7.5) 150mM NaCl, 0.2% Triton X100, and 1mM DTT, as previously described (Macauley et al, 2014). The homogenate was spun
at 14,000xg for 1 min, and the supernatant was isolated. Proteinase inhibitor cocktail (P2714,
Sigma, St. Louis, MO) and PMSF (17 µg/ml, Sigma, St. Louis, MO) were added to the
supernatant. Samples were flash frozen. For the assay, samples were thawed on ice and
centrifuged to remove particulates. Samples were then diluted to 10mg of protein/ml. Diluted
samples were further diluted 1:2 in PBS with premixed beads. The plate was incubated overnight
on a shaker at 4C. The Affymetrix multiplex plate was run and the data was reported as pg/ml.

Statistical analysis
Statistical analyses were performed using two-way or one-way ANOVA utilizing the
GraphPad Prism Software. Statistical significance is achieved at p<0.05.
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Results
Intracranial AAV2/9-hPPT1 is superior to AAV2/5-hPPT1.
Previous studies have shown that intracranial administration of AAV2/5-hPPT1
significantly improves the lifespan and motor function in the murine model of INCL (Macauley
et al, 2012; Macauley et al, 2014; Roberts et al, 2012). Recently, the AAV2/9 vector has been
utilized in CNS-related disorders due to its improved distribution and transduction efficiency
(Dayton et al, 2012; Foust et al, 2009). Both IC-AAV2/5 and IC-AAV2/9 treated animals had a
significant (p<0.001) increase in lifespan compared to untreated PPT1-/- animals. Untreated
PPT1-/- mice have a median lifespan of 8.4 months. A direct comparison between IC-AAV2/5
and IC-AAV2/9 administration showed a significant (p<0.001) improvement in median lifespan
of IC-AAV2/9 animals (13.5 months) compared to IC-AAV2/5 animals (10.6 months) (Figure
1A). Treatment with IC-AAV2/5 or IC-AAV2/9 significantly increased PPT1 enzyme activity
levels in the brain to >50% normal (Figure 1B). There was also a reduction of histological
markers of disease in the brains of both groups (data not shown, Figure 1C).

27

Figure 1. AAV2/9 is superior to AAV2/5 but does not correct the spinal cord. A) Median
lifespan of PPT1-/- (8.4 months, blue), IC-AAV2/5 (10.6 months, orange), IC-AAV2/9 (13.7
months, green), and wildtype mice (black). B) PPT1 activity in the terminal brains of ICAAV2/5 and IC-AAV2/9 mice (n> 3/group. C) Spinal cord and cortical histology from PPT1-/-,
WT, and IC-AAV2/9 for AFSM (top) and CD68 (bottom). D) Confocal images of axonal loss in
spinal cords of PPT1-/- mice. Comparison of Thy1-YFP-PPT1-/- lumbar spinal cord (left) and
Thy1-YFP-PPT1+/- lumbar spinal cord (right). Mean relative fluorescence (*p=0.013).

Spinal Cord disease in IC-treated PPT1-/- animals
Although there was an increase in PPT1 activity to >50% normal levels, the increase in
lifespan was modest. Therefore, a more thorough examination of the treated-animal’s central
nervous system was conducted. Examination of spinal cord from AAV2/9-PPT1 treated animals
revealed widespread autofluorescent storage material that was comparable to age-matched PPT128

/- mice (Figure 1C). There was also increased microgliosis (CD68) in the treated groups. To
confirm the presence of spinal cord disease, a Thy1-YFP PPT1-/- reporter mouse model was
utilized (Castelvetri et al, 2011; Feng et al, 2000). Axonal blebs and gross axonal degeneration at
7 months are detectable in the INCL spinal cord. There was a significant decrease in axonal
fluorescence in the lumbar spinal cord of PPT1 deficient mice compared to wildtype (Figure
1D). These data identified a previously unknown site of disease and uncovered a potential new
therapeutic target.

Spinal Cord Pathology in INCL
Spinal cord pathology has not been characterized in models of INCL animals, and only
one study has previously reported the possibility of spinal cord disease in INCL patients
(Santavuori et al, 1974). A temporal examination of the spinal cord from PPT1-/- and WT mice
revealed a progressive increase in AFSM in the cervical, thoracic, and lumbo-sacral regions
(Figure 2). A temporal examination of total volume of the spinal cord showed that PPT1-/- mice
had significantly decreased spinal cord volumes compared to wildtype beginning at two months.
The difference in volume increases until 3 months then the difference in total volume remains
essentially constant from three to seven months (Figure 3B, left). Grey matter volume in the
PPT1-/- mouse was significantly decreased compared to wildtype grey matter volume beginning
at two months and continues until seven months (Figure 3B, center). The white matter volume is
significantly decreased in the PPT1-/- spinal cord compared to wildtype from two to seven
months (Figure 3B, right).
Histopathological markers of disease were analyzed in the PPT1-/- spinal cords. There
was progressive astrocytosis in both the ventral and dorsal horns of the spinal cord in all three
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regions (cervical, thoracic, and lumbo-sacral) analyzed. There was a significant increase in
GFAP staining beginning at two months with the percent immunoreactivity increasing until
seven months (Figure 4A, B). Similarly, there was progressive microgliosis in the dorsal and
ventral horns in all regions of the spinal cord analyzed. There was a significant increase in CD68
staining beginning at two months and progressively increasing until seven months (Figure 5A,
B).
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Figure 2. Progressive accumulation of autofluorescent storage material. AFSM in the
cervical (left column), thoracic (middle column), and lumbo-sacral (right column) regions at 1, 3,
5, and 7 months.
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Figure 3. Regional Volume measurements of PPT1-/- spinal cords. A) Diagram for
determining total (left) and grey (right) matter volume (outlined in red). White matter volume is
determined by subtracting grey matter from total volume. B) Estimated volume for total (left),
grey (center), and white (right) matter volumes between PPT1-/- (red) and WT (blue) spinal
cords over time (**p,0.01, *** p<0.001, ****p<0.0001).
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Figure 4. Progressive astrocytosis in the spinal cord. A) Quantitative GFAP staining in the
dorsal and ventral horns of PPT1-/- (red) and WT (blue) spinal cords at cervical (top), thoracic
(middle), and lumbo-sacral (bottom) regions (**p,0.01, *** p<0.001, ****p<0.0001). B) Image
of GFAP staining in the PPT1-/- spinal cord at 1, 3, 5, and 7 months.
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Figure 5. Progressive microgliosis in the spinal cord. A) Quantitative CD68 staining in the
dorsal and ventral horns of PPT1-/- (red) and WT (blue) spinal cords at cervical (top), thoracic
(middle), and lumbo-sacral (bottom) regions (**p,0.01, *** p<0.001, ****p<0.0001). B) Image
of CD68 staining in the PPT1-/- spinal cord at 1, 3, 5, and 7 months.

Figure 6. Diagram of temporal pattern of INCL brain and spinal cord pathology

Summary of Brain and Spinal Cord INCL Pathogenesis
As we have shown, there is significant temporal and spatial INCL pathogenesis in the
spinal cord. Interestingly, spinal cord pathology precedes the brain pathology and shares many
pathological similarities (Figure 6). This is suggestive of regional specificity of INCL
progression. For example, significant disease in the thalamus is detectable prior to other regions
in the brain (Bible et al, 2004). In the brain, there is an accumulation of AFSM and
astrocytosis/microgliosis beginning at 3 months of age (Bible et al, 2004). Following AFSM
accumulation and astrocytosis/microgliosis, there is observable neuronal loss and cortical
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atrophy. As summarized in Figure 6, in the spinal cord, there is significant
astrocytosis/microgliosis and reduced volume beginning at two months. This precedes the
neurological disease in the brain by one month. Similarly, neuronal loss precedes INCL disease
in the brain. INCL has historically been considered a neurodegenerative disease. However, there
is stagnation in spinal cord volume growth suggesting a role for PPT1 in neurodevelopment.
Overall, the disease in the spinal cord suggests that this region could be significant in INCL
pathogenesis and could be a target for AAV-based gene therapy.

Differential PPT1 activity in the brain and spinal cord following intracranial and
intrathecal AAV2/9-hPPT1
In order to determine the significance of the spinal cord disease and whether the spinal
cord could be an effective therapeutic target, PPT1-/- mice were treated with intracranial
AAV2/9, intrathecal AAV2/9, or a combination of both. Initially, PPT1 activity was measured in
the brains and spinal cords of animals treated with IC-AAV2/9 or IT-AAV2/9. When the brain
and spinal cord PPT1 enzyme activity levels at one month were examined from IC-AAV2/9 and
IT-AAV2/9 mice, PPT1 activity in IC-AAV2/9 brains were significantly higher in the brain than
WT (Figure 7A). However, PPT1 activity in the IT-AAV2/9 brains were minimal at
approximately 10% of wildtype. This trend was reversed in the spinal cord with
supraphysiological levels of PPT1 enzyme activity in IT-AAV2/9 brain but near-PPT1-/- enzyme
activity in IC-AAV2/9 mice (Figure 7A).
When determining the temporal patter of expression, PPT1 activity in the wild-type brain
was approximately 150 nmol/mg/hr throughout the study. In contrast, PPT1 activity was virtually
undetectable in PPT1-/- mice brains throughout the study. IT-AAV2/9 brains had a small
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increase in brain PPT1 activity to ~2-5% of wild-type levels. In contrast, IC-AAV2/9 as well as
the combination IC/IT-AAV2/9 brains had near wild-type to supraphysiological levels of PPT1
activity (~150-450 nmol/mg/hr)(Figure 7B). Overall, the treatment groups produced a significant
(p<0.0001) difference in PPT1 activity between three to seven months (two-way ANOVA).
When comparing treatment groups, there was a significant increase in PPT1 activity in the ICAAV2/9 (p=0.0025), IC/IT-AAV2/9 (p<0.0001), and WT (p<0.0001) brains compared to PPT1/- brains. IT-AAV2/9 brains had a significant (p=0.0001) albeit small increase in PPT1 activity
compared to untreated PPT1-/- brains. There was not a significant difference between the ICAAV2/9 or IC/IT-AAV2/9 brain PPT1 activities compared to WT (p=0.68, 0.12); however, there
was a significant difference between WT and IT-AAV2/9 PPT1 activities (p<0.0001).
A reduction in the secondary elevation of other lysosomal enzymes serves as a
biochemical surrogate of therapeutic efficacy (Griffey et al, 2004). Overall, the secondary
elevations of β-glucuronidase in the treatment groups and age of the animals were observed to
have a significant (p<0.0001) effect in secondary elevations of β-glucuronidase. When
comparing treatment groups, there was a significant decrease in β-glucuronidase activity in the
IC-AAV2/9 (p<0.0001), IC/IT-AAV2/9 (p<0.0001), and WT (p<0.0001) animals compared to
untreated PPT1-/- brains. IT-AAV2/9 brains had a significant (p=0.027) albeit small decrease in
β-glucuronidase activity compared to untreated PPT1-/- brains. There was a small but significant
increase in β-glucuronidase activity between the IC-AAV2/9 (p=0.0002), IT-AAV2/9
(p<0.0001), IC/IT-AAV2/9 (p<0.0001) brains compared to WT β-glucuronidase activity levels
(Figure 7C).
Using a recently developed histochemical stain, the brains of experimental and control
animals were analyzed for the distribution of PPT1 activity. The broad, diffuse blue staining
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observed in WT brains was not present in the untreated PPT1-/- brain (Figure 8). The ICAAV2/9 brains had detectable activity in the cortex and hippocampus with weaker staining in the
thalamus, cerebellum, and other hindbrain regions. In contrast, in the IT-AAV2/9 brains, an
increase in staining in the cerebellum and brainstem was observed with little to no staining in the
forebrain. The IC/IT-AAV2/9 brains had increased staining in both forebrain and hindbrain.
There was still only low levels of PPT1 detected in the thalamus of IC/IT-AAV2/9 treated mice.

Figure 7. PPT1 and Secondary enzyme activity in treated animals. A) Analysis of PPT1
activity at 1 month in the Brain and Spinal Cord following IT-AAV2/9 and IC-AV2/9 injections.
There was reciprocal PPT1 activity between intrathecal and intracranial injections in the brain
and spinal cord (**p<0.01, *** p<0.001). B) Temporal analysis of PPT1 activity brain. PPT1
activity was increased in the brain for IC-AAV2/9 and IC/IT-AAV2/9 to near-WT or
supraphysiological levels. There was a marginal increase in PPT1 activity in the IT-AAV2/9
brain (approximately 2-5% WT levels). C) Secondary enzyme levels were normalized in the
brain. β-glucuronidase levels are increased in the untreated PPT1-/- and IT-AAV2/9 brains. ICAAV2/9 and IC/IT-AAV2/9 brains have near WT levels of β-glucuronidase.
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Figure 8. Histochemical Stain for PPT1 activity. PPT1 activity is depicted in blue. Sections
were counterstained with nuclear fast red (red).

Intracranial and Intrathecal AAV2/9-hPPT1 reduce histological markers of INCL
The accumulation of autofluorescent storage material, the histological hallmark of NCL,
was measured in all the experimental and control animals (Figure 9). A significant increase in
AFSM was observed in the PPT1-/- brain and spinal cord compared to wildtype. Following
intracranial administration, there was a significant decrease in AFSM in the M1 (motor cortex)
and in the VPM/VPL (thalamus), and no decrease in the spinal cord. In contrast, intrathecal
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administration led to a reduction of AFSM in the spinal cord but not in the brain. Consistent with
the biochemical and histochemical data, when the brain and spinal cord were simultaneously
targeted, there was a significant reduction in AFSM in the M1, VPM/VPL, and the spinal cord.

Figure 9. Autofluorescent storage material is reduced in the combination treated animals.
A) Representative images of AFSM in treated animals. Autofluorescent storage material was
examined in the S1 barrel field (S1BF) of the somatosensory cortex (top), the VPM/VPL of the
thalamus (middle), and the ventral horn of the lumbar spinal cord (bottom) of the treated
animals. B) Quantitative graph of AFSM over time examining the M1 of the motor cortex,
VPM/VPL of the thalamus, and the lumbar spinal cord.

IC-AAV2/9 and IC/IT-AAV2/9 decrease cortical atrophy
Profound brain atrophy is another hallmark of INCL. Cortical thickness (Figure 10A) and
brain weight (Figure 10B) were measured as an indicator of brain atrophy. The PPT1-/- brain
significantly decreases in weight from 3 months to 7 months when compared to wildtype. The
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decreasing brain weight was reflected in the significant thinning of the PPT1-/- cortices
compared to the WT. The IC-AAV2/9 and the IC/IT-AAV2/9 cortices did not show significant
cortical thinning or a reduction in brain weight as compared to wildtype. However, IT-AAV2/9
PPT1-/- mice had significant thinning of the cortices, and a progressive decrease in brain weight
similar to that of untreated PPT1-/-mice. The brains of the IT-AAV2/9 and untreated PPT1-/mice are not significantly different at any time point measured. Overall, both the age of the
animals and the treatment groups had a significant (p<0.0001) effect on the brain mass. When
comparing treatment groups, there was a significant increase in brain weight in the IC-AAV2/9
(p<0.0001), IC/IT-AAV2/9 (p<0.0001), and WT (p<0.0001) animals compared to PPT1-/brains. IT-AAV2/9 brains had a significant (p=0.032) albeit small increase in brain weight
compared to PPT1-/- animals. There was no difference between the IC/IT-AAV2/9 brain weights
compared to WT (p=0.862); however, there was a significant albeit small decrease in brain
weight between IC-AAV2/9 (p=0.040) and WT brains. There was a significant difference
between WT and IT-AAV2/9 PPT1 brain weights (p<0.0001).
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Figure 10. Cortical atrophy and brain mass is normalized in the combination therapy. A)
Representative images of cortices from treated animals. Sections were stained with Nissl. B)
Brain weight from treated animals over time. Brain weights for IC-AAV2/9 and IC/IT-AAV2/9
brains were essentially normal at all time points examined. IT-AAV2/9 showed a significant
reduction in brain weight compared to WT brain weight at 7 and 9 months.

Combination therapy reduces neuroinflammation in brain and spinal cord
Progressive astrocytosis and microgliosis are prominent features of INCL (Kielar et al,
2007). A significant increase in CD68 and GFAP staining in the PPT1-/- brain and spinal cord
was observed compared to wildtype (Figure 11A, B & 12A, B). In IC-AAV2/9 brains, there was
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a significant decrease in CD68 and GFAP staining in the M1 of the motor cortex and the
VPM/VPL of the thalamus. There was no decrease in CD68 or GFAP staining in the IC-AAV2/9
spinal cord. In contrast, in IT-AAV2/9, CD68 and GFAP staining were decreased in the spinal
cord but not in the brain. Similar to the accumulation of AFSM, when the brain and spinal cord
were simultaneously targeted, there was a reduction in CD68 and GFAP staining in all regions
examined: M1 of the motor cortex, VPM/VPL of the thalamus, and the lumbar spinal cord.
Cytokine and chemokine levels in brain homogenates of treated mice and controls were
measured as a complementary indicator of neuroinflammation. It had been previously shown in
INCL that there is an increase in cytokine and chemokine production as the disease progresses
(Macauley et al, 2011; Qiao et al, 2007). There were no significant differences in the levels of
tumor-necrosis factor-α (TNF-α) or interferon-γ (IFN-γ) between any of the groups (Figure
13A). In both the CXC motif and CCL motif chemokines, there was a significant increase in
PPT1-/- brains compared to wildtype brains. Neither IC-AAV2/9 nor IT-AAV2/9 alone
significantly reduced chemokine levels below that of PPT1-/- brains. There was a slight increase
above PPT1-/- chemokine levels for IT-AAV2/9 mice in CXCL1, CXCL10, CCL2, and CCL7.
In the brains of IC/IT-AAV2/9 PPT1-/- mice, there was a significant decrease in all cytokines
and chemokines to near wildtype levels (Figure 13B, C).
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Figure 11. Microgliosis is reduced in the combination treated animals. A) Representative
images of CD68 staining in treated animals. CD68 staining was examined in the S1 barrel field
(S1BF) of the somatosensory cortex (top), the VPM/VPL of the thalamus (middle), and the
ventral horn of the lumbar spinal cord (bottom) of the treated animals. B) Quantitative graph of
CD68 over time examining the M1 of the motor cortex, VPM/VPL of the thalamus, and the
lumbar spinal cord.
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Figure 12. Astrocytosis is reduced in the combination treated animals. A) Representative
images of GFAP staining in treated animals. GFAP staining was examined in the S1 barrel field
(S1BF) of the somatosensory cortex (top), the VPM/VPL of the thalamus (middle), and the
ventral horn of the lumbar spinal cord (bottom) of the treated animals. B) Quantitative graph of
GFAP over time examining the M1 of the motor cortex, VPM/VPL of the thalamus, and the
lumbar spinal cord.
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Figure 13. Cytokine analysis of treated animals at 7 months. A) Pro-inflammatory cytokines.
B) CXC motif chemokines. C) CC motif chemokines. There were no significant differences in
TNFα (with the exception of IT-AAV2/9 vs IC/IT-AAV2/9) or IFNγ between any of the groups.
There was a significant (p<0.05) increase in CXC and CC motif chemokines in PPT1-/- and ITAAV2/9. The IC-AAV2/9 chemokine levels had a trend towards normalization to wildtype
levels except in RANTES. The IC/IT-AAV2/9 chemokine levels were not significantly different
from wildtype.

Improvements in Motor function and Longevity
Gross motor function and longevity are robust endpoints used to score the therapeutic
efficacy of treatments in the INCL mouse. Gross motor function was measured by the latency for
INCL mice to fall off the rotarod. Wild-type mice remained on the rotarod for 60 seconds for the
duration of the study (Figure 14A). Untreated PPT1-/- mice displayed significant motor deficits
starting at 5 months and fell off the rotarod at 7 months with an average latency of ~10 seconds.
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After 7 months, the untreated PPT1-/- mice were unable to stay on the rotarod. Although ITAAV2/9 mice had significantly improved motor function, they began to fall off the rotarod at 7
months with an average latency to fall of 48 seconds and continued to decline until 11 months
(latency ~18 seconds). IC-AAV2/9 mice had significantly improved motor function compared to
IT-AAV2/9 animals. IC-AAV2/9 mice began to fall off the rotarod at 9 months with an average
latency to fall of ~58 seconds and continued to decline until 13 months (~14 seconds). The
combination IC/IT AAV2/9 mice had significantly improved motor function compared to either
IC-AAV2/9 or IT-AAV2/9 mice and displayed significant motor deficits starting at 15 months
with an average latency of ~50 seconds. The average latency remained constant at 17 months but
declined at 19 months to ~40 seconds. By 21 months, the remaining IC/IT-AAV2/9 mice were
unable to stay on the rotarod (Figure 14A).
Untreated PPT1-/- mice had a median lifespan of 8.4 months (Figure 14B). IT-AAV2/9
mice have a significant extension in median lifespan to 11.8 months and the IC-AAV2/9 mice
had a median lifespan of ~13.6 months. The IC/IT-AAV2/9 mice had a dramatic and significant
extension in median lifespan to 19.3 months, with the longest-lived mouse at 22 months. Only
one WT mouse died during the study with the remaining staying alive until the end of the study
(~24mo).
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Figure 14. Functional and behavioral phenotype is improved with the combination therapy.
A) Rotarod test for motor function. The PPT1 -/- mice (blue) were unable to stay on the rotarod
past 7 mo. IT-AAV2/9 mice (red) showed motor deficits at 7 month and could not stay on past
11 mo. The IC-AAV2/9 mice (green) showed deficits at 9 mo and could not stay on past 13 mo.
The combination IC/IT-AAV2/9 mice (purple) showed deficits at 15 mo and could not stay on
past 19 mo. B) Lifespan curve. The median lifespan for PPT1-/- mice (blue) was 8.4 mo. ITAAV2/9 mice (red) had an extension in lifespan of 11.3 mo (+3 mo). IC-AAV2/9 mice (green)
had an extension in lifespan of 13.7 mo (+5.3 mo). The combination IC/IT-AAV2/9 mice
(purple) had an extension in lifespan of 19.3 mo (+11.5 mo).
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Discussion
To date, pre-clinical gene therapy studies for INCL have focused on the delivery of PPT1
to the brain (Griffey et al, 2004; Griffey et al, 2006; Macauley et al, 2012; Macauley et al, 2014;
Roberts et al, 2012). Gene therapy studies utilizing a second-generation AAV vector (AAV2/5)
have shown that persistent delivery of PPT1 can significantly extend the lifespan, decrease
histological markers of disease and improve motor function in INCL mice (Macauley et al, 2012;
Macauley et al, 2014; Roberts et al, 2012). In the current study, we show that the thirdgeneration AAV vector, AAV2/9, is superior to AAV2/5. Intracranial injection of AAV2/9hPPT1 nearly normalized PPT1 activity, and reduced the secondary elevations of another
lysosomal enzyme in the brain. However, IC-AAV2/9 mice still had a significantly shortened
lifespan compared to their wild-type littermates. We hypothesized that the distribution of PPT1
was not sufficient to treat the entire CNS.
A more thorough analysis of the CNS from a separate cohort of IC-AAV2/9 mice showed
no reduction of AFSM accumulation or neuroinflammation in the spinal cord. The persistent
spinal cord disease could partially explain the limited efficacy in this and other studies when
gene therapy was limited to the brain. This study and previous studies have shown that the brain
mass of PPT1-/- mice receiving intracranial injection of an AAV vector does not significantly
decrease until near terminal; whereas the brain mass of PPT1-/- animals begin decreasing at 5
months of age (Macauley et al, 2014; Roberts et al, 2012). This suggests that the spinal cord
disease may play a significant role in the overall pathogenesis of INCL. The neurological disease
observed in the spinal cord of treated PPT1-/- mice is corroborated by the appearance of axonal
blebs and axonal degeneration using the Thy1-YFP PPT1-/- reporter mouse. The Thy1-YFPPPT1-/- reporter model will be a useful tool for the characterization of INCL spinal cord disease
and for evaluating efficacy.
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A comprehensive temporal and spatial examination of the PPT1-/- murine spinal cord
showed progressive AFSM accumulation and neuroinflammation beginning at 2 months of age
(Nelvagal et al, in preparation). The disease in the spinal cord affects both the grey matter and
white matter tracts. Interestingly, the total volume of the spinal cord in PPT1-/- animals stayed
constant from one month to seven months whereas the wildtype volumes increased. This trend
was similar for both the grey and white matter volumes. This suggests a potential
neurodevelopmental defect in the PPT1-/- animals that has not been previously characterized. In
the characterization of the INCL spinal cord pathology, astrocytosis and microgliosis were
significantly increased beginning at two months of age. This precedes the onset of disease in the
brain which begins at three months of age (Kielar et al, 2007). This finding redefines the age of
onset for INCL CNS pathology (Figure 6). Collectively, these data suggest that the spinal cord
could be an effective therapeutic target. Interestingly, a previous study showed that intrathecal
injections of recombinant PPT1 over three consecutive days was able to extend the lifespan,
improve motor function, and modestly decrease histological signs of disease in the spinal cord
(Lu et al, 2015). It is possible that some of the efficacy was due to decreasing the spinal cord
disease.
Based on these data, we performed a more comprehensive study targeting the spinal cord
alone and in combination with brain-directed gene therapy. Similar to previous studies,
intracranial AAV mediated gene therapy using an AAV2/9 vector resulted in significantly
increased longevity, improved motor function, and decreased pathology in the brain. We
discovered that there was no improvement observed in the spinal cord disease following braindirected gene therapy. While intrathecal AAV2/9 gene therapy alone resulted in decreased
pathology in the spinal cord, a significant extension in lifespan, and improved motor function,

49

the pathology in the brain was not improved. These results are consistent with the reciprocal
pattern of enzyme activity in those areas. This small increase in enzymatic activity in the brain
following intrathecal injection is not surprising given the limited distribution of AAV2/9 when
delivered intrathecally (Schuster et al, 2014).
Surprisingly, no significant differences in cytokine or chemokine levels in the brain
between the intracranial treated animals and their PPT1-/- littermates were detected even though
there was a decrease in CD68 and GFAP staining. Cytokine and chemokine levels were
measured in whole brain homogenates. Both the intracranial and intrathecal injections target
specific regions of the CNS. Therefore, INCL disease is still progressing in the CNS regions not
targeted by either therapy. It is plausible that cytokines/chemokines from the unresponsive
regions distribute throughout the brain. Not surprisingly, there were no decreases in
cytokine/chemokine levels in IT-AAV2/9 brains. Cytokine and chemokine levels were only
decreased when both the brain and spinal cord were targeted. This is consistent with the
biochemical and histological findings.
The different clinical responses of animals treated with either IC- or IT-AAV2/9 provide
important insights into the progression of INCL. As mentioned above, the significance of the
spinal cord disease to the overall pathogenesis was not known. IT-AAV2/9 corrects much of the
pathology in the spinal cord but has little effect on the brain. The fact that motor function was
improved and the lifespan was increased when histological correction was limited to the spinal
cord suggests that this aspect of INCL is clinically significant. However, it is unclear if ITAAV2/9 resulted in correction of other, yet unknown, aspects of INCL as well. For example, it is
not known if INCL affects the peripheral nervous system (PNS). Intrathecal injection of AAV
vectors has been shown to deliver transgene products to the sciatic nerve (Federici et al, 2012;
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Jacques et al, 2012; Schuster et al, 2014; Vulchanova et al, 2010). It is possible that IT-AAV2/9
is affecting the PNS in INCL. These data also demonstrate that the brain is the most severely and
acutely affected region of the CNS, since limiting therapy to the brain is clearly more effective
than targeting the spinal cord.
When the intracranial and intrathecal injections are combined, there is a dramatic and
significant extension in lifespan and improvement in motor function compared to either therapy
alone. This is most likely due to the broader distribution of the AAV-hPPT1 vector in the CNS.
Taken together, these data suggest that it will be necessary to treat both the spinal cord and brain
disease to achieve maximum efficacy. Interestingly, these data also show that targeting both
regions results in synergistic improvements. For example, if the modalities were simply additive,
the extension in lifespan would be approximately 16.7 months rather than the 19.3 months
observed. Similarly, the improvement in motor function also suggests a synergistic effect. The
age at which IC/IT-AAV2/9 mice begin to fall off the rotarod (15 months) is greater than the
sum of the increases observed with the IT-AAV2/9 (7 months) or IC-AAV2/9 (9 months) mice.
Although the combination therapy significantly improves lifespan and motor function,
the IC/IT-AAV2/9 mice have a reduced lifespan compared to their wildtype littermates. These
data suggest that the IC/IT-AAV2/9 mice may either be succumbing to disease outside of the
central nervous system or that the minimal correction of the thalamus/mid-brain is not sufficient
to prevent neurodegeneration. These data suggest that an intracranial or intrathecal
administration route alone is not sufficient to correct the entire CNS (Rosenberg et al, 2014). It
has been shown that there is cardiac dysfunction in models of Batten disease and INCL (personal
communication with Dr. Jonathan Cooper, (Galvin et al, 2008)) as well as systemic metabolic
defects (Woloszynek et al, 2007). Targeting these secondary disease modalities using small
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molecule drugs or recombinant PPT1 in combination with gene therapy may further extend the
lifespan and quality of life for treated-INCL mice. Simultaneously targeting multiple pathogenic
mechanisms or different diseased compartments has proven effective in INCL (Macauley et al,
2012; Macauley et al, 2014; Roberts et al, 2012) and other LSDs (Biswas & LeVine, 2002;
Hawkins-Salsbury et al, 2011; Hawkins-Salsbury et al, 2015; Jeyakumar et al, 2001; Lee et al,
2007; O'Connor et al, 1998; Passini et al, 2007; Reddy et al, 2011).
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Chapter 3: Cell-limited expression of PPT1

This chapter is adapted from the following manuscript:
Shyng C, Macauley SL, Sands MS. Cell-limited expression of PPT1. In Preparation
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Introduction
Soluble lysosomal enzymes are translated and glycosylated in the endoplasmic reticulum
then transported to the Golgi apparatus where terminal mannose residues are phosphorylated at
the six position (M6P). Binding to the M6P /IGF II receptor in the Golgi targets the
phosphorylated enzymes to the lysosome through the endolysosomal pathway. The enzymereceptor complex uncouples at acidic pH releasing the enzyme for proper lysosomal activity. It
has been shown that soluble lysosomal enzymes are secreted from a parent cell and can be
captured by neighboring cells via the M6P/IGFII receptor on the plasma membrane (Barton &
Neufeld, 1971; Cantor & Kornfeld, 1992; Hickman & Neufeld, 1972; Neufeld & Fratantoni,
1970). Trafficking of the secreted enzymes to the neighboring lysosome allows enzymatic
functionality to be restored (Dahms et al, 1989; Neufeld, 1980; Neufeld, 2006; Verkruyse &
Hofmann, 1996; Willingham et al, 1981). This inter-cellular trafficking of lysosomal enzymes,
termed ‘cross-correction’, forms the basis of therapeutic approaches using cell-based, virusbased, or enzyme replacement therapies. While ‘cross-correction’ enhances treatment, it prevents
the cell-autonomous study of enzyme deficiencies in lysosomal storage diseases (Sands, 2013;
Sands & Davidson, 2006).
For this study, we utilized the soluble lysosomal hydrolase palmitoyl-protein
thiosesterase-1 as a model enzyme to study cell autonomy in a lysosomal storage disorder. In
humans, deficiency of PPT1 results in infantile neuronal ceroid lipofuscinosis (INCL), a
progressive neurodegenerative disease (Hofmann et al, 1999; Vesa et al, 1995).
Histopathological characterization of PPT1 deficiency reveals an accumulation of
autofluorescent storage material (AFSM), neuronal death, glial activation, and
neuroinflammation. This pathology results in progressive clinical deficits in vision, motor
function, and cognition. A PPT1-deficient mouse model closely mimics human INCL (Bible et
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al, 2004; Gupta et al, 2001). Understanding the role of specific cell types in INCL pathology may
lead to an improvement in targeted therapeutics in humans. Using proteomics and metabolomics,
studies have shown that PPT1 deficiency leads to alterations in global cellular and metabolic
expression profiles. However, modeling cellular and metabolic profile changes in specific cell
types has been lacking due to ‘cross-correction’ (Aby et al, 2013; Scifo et al, 2015; Tikka et al,
2016). By sequestering PPT1 in individual cells, we may begin to understand the role of specific
cell types in disease progression, as well as the interactions of PPT1 sufficient and deficient cells
in a hypothetical therapeutic environment.
To overcome ‘cross-correction’, we have engineered a chimeric, lysosomal membranetethered form of PPT1 using the transmembrane domain/signaling peptide of lysosomalassociated membrane protein-1 (LAMP1). The transmembrane domain/signaling peptide has
been shown to be necessary and sufficient for lysosomal targeting of LAMP1, and may be used
as a targeting and retention mechanism for secreted lysosomal hydrolases (Guarnieri et al, 1993;
Rohrer et al, 1996). A similar approach has been used to create a milder form of Neiman-Pick
A/B disease (acid sphingomyelinase (SMase) deficiency) (Marathe et al, 2000). In our model, we
created a chimeric form of PPT1 that is tethered to the lysosomal membrane and would be
expressed in a cell-specific manner (PPT1-LAMP1). To accomplish cell-specificity, we
employed a genetic approach by inserting a loxP-STOP-loxP sequence into the transgene that
would prevent both transcription and translation of PPT1-LAMP1 unless in the presence of Cre
recombinase.
We show here that membrane tethered PPT1 retains enzyme activity and is capable of
preventing the biochemical, histological, and behavioral phenotype of INCL when expressed
ubiquitously in vivo. Unfortunately, the transgene rearranged leading to Cre unresponsiveness,
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and unregulated and ubiquitous PPT1-LAMP1 expression. Nonetheless, this study demonstrates
a proof-of-principle that this general methodology is a viable approach to address questions
regarding the role of specific cell types in the progression of INCL.

Materials and Methods
PPT1-LAMP1 transgene
A diagram of the PPT1-LAMP1 transgene is shown in Figure 1. The transgene includes
the promoter and first intron of the chicken β-actin gene, a LoxP-STOP-LoxP sequence from
pBS302 (Addgene, Cambridge, MA), the human PPT1 cDNA genetically linked to a 120bp
sequence encoding the transmembrane domain and lysosomal localization sequence of LAMP1,
a six-glycine linker region, followed by a rabbit β-globin polyadenylation signal.

Generation of the PPT1-LAMP1 transgenic mouse
Transgenic mice were generated by microinjection of the transgene into C57Bl/6
embryos. This service was performed by the Transgenic Knockout Microinjection Core at
Washington University School of Medicine. Founder lines were identified by PCR using primers
flanking the PPT1-LAMP1 junction. Germline founder lines were identified by breeding
transgene positive mice to PPT1-/- mice. Germline transgene transmission was identified using
the aforementioned PCR primers. When possible, the transgenes were fixed on the PPT1-/background. Congenic C56Bl/6 wild-type mice were used as controls.

Lentiviral production of PPT1-LAMP1
A 3rd generation SIN lentiviral vector was created for in vitro experiments (Dull et al,
1998; Zufferey et al, 1998). Briefly, the transfer plasmid contained the phosphoglycerate kinase
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(PGK) promoter, the target gene, a SV40 poly(A) site, and a puromycin resistant cassette. The
target gene contained wild-type PPT1 or PPT1-LAMP1. The negative-control, empty lentiviral
vector did not contain a target gene. The transfer plasmid was transiently transfected in
combination with pMD-Lg/pRRE, pRSV-Rev, and pMD2.G plasmids into HEK293T cells by
calcium-phosphate transfection. Media containing lentivirus was collected and concentrated
using ultracentrifugation as previously described (Dull et al, 1998; Zufferey et al, 1998).
Lentiviral titers were assessed using serial dilutions and puromycin selection.

Transwell experiment
Cross-correction experiments were performed using a transwell system (Corning,
Corning, NY). Briefly, PPT1-/- cells were plated on the bottom well, transduced for 24 hours,
then exposed to puromycin after 72 hours post-transduction. The bottom well cells were allowed
to become confluent. Untransduced PPT1-/- cells were plated on the transwell inserts in a
separate dish, and were transferred into the experimental plate. Three days post-incubation, cells
and media were collected for PPT1 enzyme activity. Cells were lysed in 10mM Tris pH 7.5,
150mM NaCl, 0.2% Triton X-100 via three freeze-thaw cycles. Cells were centrifuged and
supernatant collected for enzyme activity. Cross correction experiments using primary dermal
fibroblast cell cultures from one of the transgenic animals were similarly performed with the
primary cells being plated on the bottom wells.

RNA isolation, RT-PCR, and Sequencing
RNA was isolated from brain, heart, and liver using TRIzol (Thermo Fischer, Waltham,
MA) as described. Briefly, samples were homogenized in TRIzol. RNA was isolated, and cDNA
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was generated using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fischer,
Waltham, MA). RT-PCR was performed using primers flanking the 6-glycine region. The
forward primer was in the PPT1 sequence and the reverse was in the LAMP1 sequence. DNA
sequencing was performed using the Protein and Nucleic Acid Chemistry Laboratory using
Sanger di-deoxy sequencing. The sequencing primers flanked the loxP-STOP-loxP sequence.
qPCR was performed on genomic DNA. Standards for copy number were generated from serial
dilutions of the stock PPT1-LAMP1 plasmid. Quantitation for copy number was generated as
previously described (Joshi et al, 2008).

SDS-PAGE/Western Blot
To confirm expression of PPT1-LAMP1 protein, lentiviral transduced cells or primary
cell lines derived from a transgenic animal and control lines were isolated and homogenized in
50mM Tris-HCl pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 150mM NaCl, and 2mM EDTA (RIPA buffer). Cells were spun at 14000xg for 1 min
and the supernatant was collected. The cell supernatant was diluted to 2µg protein/ul and 30ug of
protein were loaded onto 12% SDS-PAGE gels (Bio-Rad, Hercules, CA). Protein was transferred
onto PVDF (Porex Filtration Group, Fairburn, GA) membrane and probed for human PPT1
(Abcam 89022; 1:1000) or the cytoplasmic domain of LAMP1 (Sigma L1418; 1:1000).
Secondary antibodies for mouse-horseradish peroxidase (HRP) or rabbit-HRP were used. Pierce
ECL Western Blotting Substrate (ThermoFisher, St. Louis, MO) was used to detect the
antibodies.

PPT1 Enzyme Activity and Secondary Enzyme Elevations
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Three mice each from transgenic and control groups were euthanized via lethal injection.
Mice were transcardially perfused with phosphate-buffered saline (PBS) until the liver was
cleared of blood. Portions of visceral organs (heart, liver, spleen, kidney, eye) were flash frozen
for subsequent biochemical analyses. Additional tissue samples were fixed in 4%
paraformaldehyde in PBS solution for 24-hr fixation then cyroprotected in 30% sucrose solution
in Tris-buffered saline (TBS). The brain was removed, weighed, and bisected sagittally; the left
hemisphere was flash frozen while the right hemisphere was fixed/cyroprotected. PPT1 assays
were performed on the brain, heart, and liver as previously described using the 4-MU-palmitate
fluorometric assay and normalized to total protein (Griffey et al, 2004). Secondary elevations of
β-glucuronidase was determined using 4-MU-β-D-glucuronide fluorometric assay and
normalized to total protein as previously described (Roberts et al, 2012). Significance was
determined using a two-way ANOVA followed by a Bonferroni post-hoc analysis for all
enzyme assays.

Immunofluorescence
Immunofluorescence was performed as previously described (Hawkins-Salsbury et al,
2013). Briefly, cells were plated on poly-lysine coated coverslips. Cells were fixed then
permeabilized with a 0.01% Triton X-100 in TBS solution. After blocking with 5% normal goat
serum in TBS, cells were stained for human PPT1 (rabbit anti-rat), the cytoplasmic domain of
Lamp1 (rat anti-mouse), and DAPI. Primary antibodies were detected with Alexa Fluor 488
(anti-rat) and 555 (anti-rabbit).

Autofluorescent Storage Material
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AFSM was imaged as previously described (Griffey et al, 2004). Briefly, fixed and
cryoprotected tissue was frozen in Optimal Cutting Temperature compound (OCT, Tissue-tek,
VWR, Radnor, PA). Twelve-micrometer sections were cut and placed onto Superfrost slides.
The slides were allowed to dry for 24 hrs at room temperature. The OCT was washed off using
diH2O, and allowed to dry. Slides were coverslipped using Vectashield Antifade mounting
medium (Vector Labs, Burlingame, CA). Sections were then imaged using confocal microscopy.

Lifespan, Rotarod, and Electroretinography
Longevity was assessed in control groups and transgenic mice (n=10-11 mice/group).
The lifespan study was determined by death or euthanasia at one year. A Kaplan-Meier lifespan
curve was used to measure survival and significant differences were determined using a log-rank
analysis (p<0.05).
Transgenic and control mice (n=10) were tested on a constant-speed rotarod (3 rpm) at 7
months as previously described (Dearborn et al, 2015). Statistical significance was determined
using one-way ANOVA at each time point followed by a Bonferroni post hoc test.
Electroretinography (ERG) was performed by the Vision Core at Washington University
in St. Louis as previously described (Griffey et al, 2005; Heldermon et al, 2007). Briefly, mice
were dark-adapted for mixed rod/cone ERG for a minimum of 2 hours or light adapted for 20
minutes for pure cone ERG measurements. Mice were then anesthetized. A recording electrode
was placed on the cornea and a reference electrode was inserted subcutaneously behind the ear.
Mice were exposed to flashes of light and the a- and b-waves were recorded using the UTAS-E3000 LKC testing and analysis system (LKC Technologies, Gaithersburg, MD). b-wave
amplitudes were recorded in microvolts and reported.
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Results
Lysosomal Membrane-Tethered PPT1
PPT1 is a soluble lysosomal hydrolase that can be secreted then endocytosed by
neighboring cells. Studying PPT1 function in a cell autonomous manner is difficult due to ‘crosscorrection’. Therefore, we generated a tethered form of PPT1 by anchoring the enzyme to the
lysosomal membrane (Figure 15A). We genetically engineered the tethered PPT1 such that the
enzyme is within the lumen of the lysosome and that the C-terminus of PPT1 is tethered to the
transmembrane domain and C-terminus of the lysosomal acidic membrane protein-1 (LAMP-1)
via a six glycine linker (PPT1-LAMP1). Conceptually, the six-glycine linker region should not
have steric hindrance nor disallow PPT1 to function properly. The transmembrane domain and
C-terminus of LAMP-1 is a lysosomal membrane protein and has been shown to be targeted to
the lysosome via the YQTI amino-acid motif (Figure 15B).
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Figure 15. Mockup and Sequence of PPT1-LAMP1. A) Ribbon diagram of PPT1-LAMP1.
PPT1 is in the lumen of the lysosome (globular structure). It is connected to the C-terminus and
transmembrane domain of LAMP1 (pink) by a six glycine linker (light blue). B) Amino acid
sequence of PPT1-LAMP1. The human PPT1 sequence (green) is genetically tethered to the
transmembrane domain and C-terminus of LAMP-1 (pink) by the six-glycine linker (light blue).
The lysosomal targeting motif is underlined.

PPT1-LAMP1 function in vitro
PPT1-/- fibroblasts were transduced in vitro with lentiviral constructs containing hPPT1LAMP1, WT-hPPT1, or a negative-control empty vector. Lysosomal localization of PPT1LAMP1 was confirmed using immunofluorescence by staining against human PPT1 and LAMP1 (Figure 16A). A western blot was performed on protein homogenates from these cells and
showed that there was an increase in molecular weight of the hPPT1-LAMP1 (~40 kDa)
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compared to the wildtype human PPT1(~32-36 kDa). This was consistent with the additional
molecular weight of the LAMP1 transmembrane domain and six-glycine linker (~5 kDa).
Blotting against the C-terminus of LAMP-1, both the endogenous LAMP1 (~120 kDa) and a
signal at ~40 kDa were detected. This was the same molecular weight as PPT1-LAMP1 detected
with the anti-PPT1 antibody (Figure 16B).
To confirm that PPT1-LAMP1 retained enzyme activity and was not secreted, a transwell
experiment was performed where the bottom well contained the lentiviral-transduced cells and
the transwell contained untransduced PPT1-/- cells. There was little to no PPT1 activity in cell
transduced with the empty vector (Figure 15C). Following transduction with wildtype PPT1,
significantly higher PPT1 activity (~400 nmol/µg/hr) was detected compared to the empty vector
cells. After transduction with the PPT1-LAMP1 vector, the level of PPT1 activity in the
transduced cells was comparable to the WT-PPT1 transduced cells. Lastly, PPT1-LAMP1 was
not secreted from the transduced cells. In the wild-type hPPT1 transduced wells, there was an
increase in PPT1 activity in the transwell cells (~5% of wild-type levels). However, in the PPT1LAMP1 transduced wells, there was little to no detectable activity in the transwell cells from the
PPT1-LAMP1 well. In the negative control, as expected, PPT1 enzymatic activity was
undetectable (Figure 16C).
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Figure 16. In vitro characterization of PPT1-LAMP1. A) Immunofluorescence of PPT1
(green, left) and LAMP-2 (red, center). Co-localization of PPT1 and LAMP2 is in yellow (right).
B) Expression of PPT1-LAMP1 in vitro. PPT1-/- cells were transduced with lentivirus
containing hPPT1-LAMP1 or hPPT1. The left panel is probed for anti-hPPT1. hPPT1 has a
predicted molecular weight of ~32 and 36 kDa, and hPPT1-LAMP1 is predicted at ~40 kDa. The
right panel was probed for the C-terminus of LAMP-1. LAMP-1 signal was detected in the lane
from hPPT1-LAMP1 transduced cells. C) Transwell experiment for ‘cross-correction’. Cells
were transduced with empty, WT-PPT1, or PPT1-LAMP1 lentiviral vectors. There was a
significant increase in enzyme activity in the WT-PPT1 compared to empty. WT-PPT1 cells and
PPT1-LAMP1 cells had similar levels of activity. There was a significant increase in PPT1
activity in the transwell inserts in the WTPPT1 transwell compared to Empty and PPT1-LAMP1
transwells (p<0.05).

Generation of a PPT1-LAMP1 transgenic animal
To study the role of specific cell to the pathogenesis of INCL in vivo, transgenic animals
harboring the PPT1-LAMP1 transgene were generated. For cell-specificity, we included a loxPSTOP-loxP sequence within our transgene (Figure 17A). In vitro transfection of PPT1-/- cells
with a Cre-recombinase plasmid or the transgene-containing plasmid alone resulted in no
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increase in PPT1 activity levels compared to PPT1-/- cells. However, when transfected together,
there was a significant increase in PPT1 activity to near WT-PPT1 activity levels (Figure 17B).
This confirmed that the transgene-containing plasmid was Cre-responsive.
PPT1-/- animals harboring the transgene were generated after confirmation of in vitro
feasibility. Transgene-positive founder animals were identified by PCR analysis for the PPT1LAMP1 junction (Figure 18A, B). Eight transgene-positive animals were identified. Five founder
lines demonstrated germ-line transmission. However, three founders were unable to establish
productive colonies. Two founders (Founder #38 and #42) were able to generate colonies.
Founder #38 did not express PPT1-LAMP1 in the presence or absence of Cre-recombinase.
Surprisingly, a PPT1 enzymatic assay of Founder #42 (F42) brain resulted in supraphysiological
levels of PPT1 activity in the absence of Cre recombinase (data not shown). While unfortunate,
F42 could be utilized as a proof-of-principle transgenic model of sequestered PPT1.

Figure 17. Generation of a cell-specific transgene. A) Structure of the transgene. LoxP sites
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are shown in triangles. B) The transgene was first tested in vitro. There was not a significant
increase in PPT1 activity in the PPT1-/- cells transfected with the transgene alone or the Crecontaining plasmid alone. There was a significant increase in PPT1 activity when the transgene
and the Cre-containing plasmid were transfected together. pCAGGs-hPPT1 plasmid was used as
a transfection control (p<0.05).

Founder #42 analyses
Molecular and biochemical characterization of F42 revealed a possible spontaneous
recombination, and expression of the PPT1-LAMP1 transcript and protein. Further
characterization of the transgene was performed using primers flanking the loxP-STOP-loxP
sequence (Figure 18A). Surprisingly, a band of approximately 260bp was detected. This
fragment was consistent with recombination of the loxP sites (Figure 18C). Further DNA
sequencing of the fragment confirmed Cre-independent recombination. Approximate copy
numbers were calculated using quantitative PCR. The qPCR confirmed an approximate 11
transgene copies per genome.
Using RT-PCR, PPT1-LAMP1 mRNA was detected in the brain, heart, and liver of F42
mice but was undetectable in wildtype or PPT1-/- mice (Figure 19A). Western blot analysis was
performed on primary dermal fibroblasts to confirm the presence of PPT1-LAMP1. In F42
primary fibroblasts, a protein of ~36-40 kDa was detected with an anti-hPPT1 antibody (Figure
19B, left). Similarly, a protein was detected at ~40 kDa with an anti-LAMP1 antibody directed
towards the C-terminus domain (Figure 19B, right). This was consistent with the aforementioned
in vitro studies that reflected the increase in size due to the addition of the LAMP-1 C-terminus
and transmembrane domain. Similarly sized proteins were not detected in the primary dermal
fibroblasts from murine PPT1-/- and wild-type mice. However, the PPT1 signal was detected in
human fibroblast cultures. The two bands likely correspond to unglycosylated (lower band) and
glycosylated PPT1 (Das et al, 2001; Lyly et al, 2007). There was a faint band in the F42
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homogenates that migrated at approximately the same position as the unglycosylated PPT1 in the
human fibroblasts. With further characterization of F42, dermal fibroblasts using a transwell
system showed that PPT1-LAMP1 does not ‘cross-correct’ (Figure 19C). Approximately 10
nmol/µg/hr PPT1 activity was detected in the transwell cells exposed to media from the wildtype cells. In contrast, no PPT1 activity was detected in the transwell cells exposed to media
from the F42 cells even though F42 dermal fibroblasts had ~6-fold greater PPT1 activity
compared to wildtype cells.

Figure 18. Generation of transgenic animals and identification of loxP site recombination.
A) Structure of the transgene and position of primers. Primers used for the identification of
recombination are shown in red. Primers used for identification of transgenic animals are shown
in forward: yellow and reverse: red. Primers used for RT-PCR are shown in blue. B) PCR gel
image identifying all the transgene positive founders. Lane 1: pBR322-MSPI digest ladder, Lane
2: positive control using the transgene plasmid, Lane 3: pCAGGs-PPT1 plasmid, Lane 4-11:
transgene founder lines. C) PCR gel identifying spontaneous recombination in Founder #42.
Lane 1: 1Kb ladder, Lane 2: pBR322-MSPI digest ladder, Lane 3: in vitro Cre recombinase and
transgene plasmid, Lane 4: genomic DNA isolated from F42 brain, Lane 5: genomic DNA
isolated from F42 Liver, Lane 6: genomic DNA isolated from PPT1-/- brain, Lane 7: genomic
DNA isolated from PPT1-/- liver, Lane 8: negative control.
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Figure 19. In vitro characterization of F42. A) RT-PCR of brain, heart, and liver from PPT1-/-,
F42, and WT mice for the PPT1-LAMP1 mRNA transcript. B) Western blot for PPT1-LAMP1
expression. Protein expression of PPT1-LAMP1 was conducted on primary dermal fibroblasts.
The left panel was probed for anti-human PPT1. A strong signal was detected at ~40 kDa in the
F42 lane, and at the predicted ~32 (unglycosylated) and ~36 kDA (glycosylated) in the human
control fibroblasts. The right panel was probed for the C-terminus of LAMP-1. There was a
signal at ~120kDa (endogenous LAMP1) in all lanes and ~40kDA (PPT1-LAMP1) signal in the
F42 lane. C) Transwell experiment for ‘cross-correction’. Primary dermal fibroblast cells were
used. There was a significant increase in enzyme activity in the WT-PPT1 compared to PPT1-/cells. F42 cells have ~6-fold greater levels of PPT1 activity compared to WT cells. There was an
increase in PPT1 activity in the transwell inserts in the WTPPT1 transwell compared to PPT1-/and F42 transwells.

PPT1-LAMP1 expression in vivo is ubiquitous and prevents AFSM
A survey of tissues for PPT1 activity and secondary enzyme elevations was conducted in
Founder 42 mice. Supraphysiological levels of PPT1 activity were detected in the brain and
heart, and lower enzymatic activity in the kidney and spleen compared to wildtype. Surprisingly
we detected very low PPT1 activity in the liver (Figure 20A). As previously shown, there was a
secondary elevation in β-glucuronidase activity in the PPT1-/- brain, heart and liver as compared
to wildtype (Griffey et al, 2004). This secondary elevation was restored to wildtype β-
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glucuronidase activity levels in the brain and heart of F42 animals. However, there was not a
significant reduction in the secondary elevation of β-glucuronidase activity in the liver compared
to the PPT1-/- liver (Figure 20B). Autofluorescent storage material was examined in the brains
and livers of PPT1-/-, WT, and F42 mice. As expected, there was widespread AFSM throughout
the brain and liver of PPT1-/- animals and none detected in the wildtype animals. Accumulation
of AFSM was not detected in the cortex, hippocampus, thalamus, or cerebellum of F42 brains.
However, there was abundant AFSM throughout the liver in hepatocytes and cells of the
reticuloendothelial system (Figure 20C & 20D).

Figure 20. Biochemistry and Histology in F42. A) PPT1 enzyme activity tissue survey.
Supraphysiological levels of PPT1 activity were detected in the brain and heart. Near normal
levels were detected in the kidney, and ~50% activity in the spleen. The liver had very low
activity. B) β-glucuronidase activity in the brain, heart, and liver from F42 and controls. There
was a significant increase in β-glucuronidase activity in the brain and liver of PPT1-/- animals
compared to WT (p<0.05). β-glucuronidase activity was normalized to WT levels in the F42
brain, however, the β-glucuronidase activity was not reduced in F42 liver. The heart showed a
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small increase in β-glucuronidase activity in PPT1-/- animals but this increase was not
statistically significant. There appeared to be decreased β-glucuronidase activity in the F42 heart.
C) AFSM accumulation in F42 and control brains. Representative images show AFSM
accumulation in PPT1-/- brains (cortex and cerebellum). AFSM was not detected in F42 cortex
or cerebellum. D) AFSM accumulation in F42 and control liver. Representative images show
AFSM accumulation in PPT1-/- and F42 livers.

PPT1-LAMP1 ubiquitous expression in vivo prevents behavioral decline and
extends longevity
PPT1-/- mice showed a significant decline in ERG amplitudes and motor function by 7
months of age, and are terminal by ~8.5 months. Physiological characterization of F42 showed
that PPT1-LAMP1 expression prevented the decline in both dark-adapted and light-adapted ERG
amplitudes (Figure 21A). At 7 months, the motor function of F42 animals, as measured by the
latency to fall off the rotarod, was identical to wildtype mice (Figure 21B). Lastly, the F42 mice
are able to live to at least one year without any motor deficits or other obvious clinical signs of
disease (Figure 21C).
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Figure 21. Functional and Clinical parameters of F42. A) Electroretinography of F42 and
control eyes. There was a significant increase in b-wave amplitudes in the light-adapted
(p<0.001) and dark-adapted (p<0.001) in WT compared to PPT1-/- mice. Similarly, there was a
significant increase in b-wave amplitudes in light-adapted (p<0.01) and dark-adapted (p<0.001)
in F42 compared to PPT1-/-. There was no significant difference between F42 and WT B)
Rotarod of F42 mice showed no deficit in motor function at 7 months of age. C) The lifespan of
F42 mice (orange) was not reduced compared to WT animals out to one year; PPT1-/- animals
had a median lifespan of 238 days (blue).

Discussion
Lysosomal storage diseases are simple monogenic diseases that present with a complex
clinical phenotype. This is because lysosomal enzymes are ubiquitously expressed and, when
deficient, affect many cell types. A more thorough understanding of the role individual cell types
play in the disease process will allow for the rational development of more effective therapies.
While ‘cross-correction’ has been a boon for therapy, it interferes with our ability to address
basic biological questions about the role of specific cell types in disease progression. Any
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attempt to correct the disease in a cell-specific manner would yield inconclusive, confounding
results. Therefore, in this study, a novel method was employed to prevent cross-correction in an
attempt to limit PPT1 expression to specific cell types.
A previous study by Marathe et al, (2000) showed that it was possible to prevent the
secretion of sphingomyelinase, another soluble lysosomal hydrolase. Sphingomyelinase has been
shown to be processed differentially depending on whether it will be targeted to the lysosome or
secreted. In an effort to sequester the secreted form, SMase was tethered to the lysosomal
membrane using the C-terminus of LAMP-1. The authors created a transgenic/knockout model
that had modest lysosomal SMase activity in the brain (approximately 20% WT) and lower
activity in visceral tissues (1-14%). This model had no evidence of neurological disease but
widespread systemic disease. The original goal of their study was to eliminate the secreted form
ubiquitously, which resulted in a hybrid model of Neimann-Pick A/B with visceral disease but
no neurological disease.
In the current study, the original goal was to achieve cell-specific expression of PPT1.
However, due to spontaneous rearrangement, a model with ubiquitous expression of tethered
PPT1 was created. This model (F42) had AFSM in the liver but was otherwise biochemically,
histologically, and clinically normal. This demonstrates proof-of-principle that PPT1-LAMP1
can hydrolyze its normal substrates and prevent INCL.
Tethering of PPT1 to the lysosomal membrane using the transmembrane domain and Cterminus of the LAMP-1 protein does not alter the enzymatic activity of PPT1. In addition,
PPT1-LAMP1 was faithfully trafficked to the lysosome where it functions similarly to native
PPT1. Importantly, PPT1-LAMP1 does not ‘cross-correct’ neighboring cells. In both in vitro
experiments using either transduced cells or primary fibroblasts from F42, PPT1 activity was
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expressed six-fold greater than normal and no enzymatic activity was detected in the transwell
insert.
Ubiquitous expression of PPT1-LAMP1 in vivo was capable of preventing the
accumulation of AFSM in the brain. This indicated that restoration of PPT1 by tethering it to the
lysosomal membrane was sufficient in preventing the accumulation of AFSM. Moreover, the
expression of PPT1-LAMP1 ubiquitously was able to prevent the onset of the major
clinical/behavioral signs such as shortened lifespan, reduced visual function, and motor
dysfunction. Similar to the in vitro experiments, there was also no evidence of PPT1-LAMP1
secretion or ‘cross-correction’ in vivo. The brain and heart of F42 have PPT1 activity
approximately 10-fold greater than normal, while kidney and spleen have nearly normal and
~50% normal levels of activity, respectively. The liver only expresses ~5% normal levels of
PPT1 activity. On histological examination, the liver of F42 has widespread AFSM
accumulation. Given the high level of expression in other tissues, if PPT1-LAMP1 were capable
of ‘cross-correction’, we would predict that the liver would have higher levels of activity and no
AFSM accumulation.
In order to accomplish our original goal of generating a mouse model that would have
cell-specific expression of PPT1LAMP1, a loxP-STOP-loxP system was utilized. However,
during the initial characterization of the transgenic lines on a PPT1-/- background, enzymatic
activity was detected in the absence of Cre-recombinase indicating a possible spontaneous
recombination of the loxP sites. Generation of F42 utilizing the conventional transgenic
approach led to multiple copies of the transgene (~11 transgene copies/genome). It has been
shown that this method results in the generation of multiple head-to-tail copies (Haruyama et al,
2009). It is possible that the repeat sequences in the concatamers make the transgene prone to
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recombination. Consistent with this hypothesis, it has been shown that direct sequence repeats
can to lead to deletion of the internal sequence (i.e. loxP-STOP-loxP) (Bill & Nickoloff, 2001;
Hendricks et al, 2003; Wurtele et al, 2005). Such an occurrence could lead to excision of the
loxP-STOP-loxP region and allow for transcription of the transgene. The varying levels of
expression among tissues could be due to the integration site. One potential solution to this
problem would be to knock-in the transgene into the ROSA26 locus to control for copy number
and random integration.
While the transgenic model may not allow for the study of cell autonomy in an in vivo
setting, the model provides evidence that this basic approach is sound. In addition, the generation
of a constitutively expressing, near-ubiquitous PPT1LAMP1 will allow for the study of cell-cell
interactions in an in vitro environment. Lastly, this concept of tethering a soluble lysosomal
enzyme to the lysosomal membrane may be applied to other LSDs and improve our
understanding of cell autonomy in LSDs.
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Chapter 4: Summary, Conclusions, and Future
Directions
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Summary and Conclusions
Infantile neuronal ceroid lipofuscinosis is an inherited metabolic disorder that is caused
by a deficiency in the soluble lysosomal hydrolase palmitoyl-protein thioesterease-1 (PPT1)
(Haltia et al, 1973b; Santavuori et al, 1973; Vesa et al, 1995). Deficiency in PPT1 leads to
lysosomal distention, accumulation of AFSM, and cellular dysfunction. Ultimately, PPT1
deficiency leads to complex clinical signs. The development of the PPT1-/- mouse model has led
to a much deeper understanding of disease pathogenesis as well as development of pre-clinical
treatments (Gupta et al, 2001). Over the past 15 years, the field has benefited from the
characterization of neuropathology in the PPT1-/- mouse. Studies, to date, have shown that INCL
disease in the brain is progressive both temporally and spatially (Bible et al, 2004; Kielar et al,
2007; Macauley et al, 2009). There is astrocytosis, neurodegeneration, and neuroinflammation.
This histopathology correlates with the clinical signs of disease such as visual deficits, motor
dysfunction, and reduced lifespan. Due to the cortical atrophy and dramatic decrease in brain
mass, the NCL field has largely focused on disease within the brain while the disease in the
spinal cord has been largely overlooked. Similarly, detailed characterization of the peripheral and
autonomic nervous systems as well as the systemic disease have not been conducted.

A new target and effective therapy for INCL
This study identified a novel region of disease and sought to treat it using gene transfer.
In this study, we transitioned from the second generation AAV2/5 vector to the third generation
AAV2/9 vector. The AAV2/9 vector has been shown to have improved distribution and
transduction efficiency compared to previously used gene therapy vectors (Dayton et al, 2012;
Schuster et al, 2014). Given the AAV2/9 vector’s superior characteristics, we predicted that the
lifespan of PPT1-/- mice receiving intracranial injections would have been extended longer than
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the two months observed. This prompted us to perform a more detailed examination of the spinal
cord in treated and untreated mice in collaboration with Dr. Jonathan Cooper’s lab at King’s
College, London.
A more comprehensive examination of the PPT1-/- mouse spinal cord revealed gross
anatomical changes as well as more subtle histological changes. It was revealed that there was a
similar but earlier onset of histopathology in the spinal cord compared to the brain. While the
volume of white matter increased temporally in the PPT1-/- spinal cord, the volume did not
approach that of wild-type mice. Interestingly, the grey matter in the PPT1-/- spinal cord
decreased whereas the wildtype grey matter increased. The hallmark of INCL, autofluorescent
storage material, was prevalent in the grey matter and progressively increased starting as early as
two months. Astrocytosis and microgliosis were observed as early as two months of age
throughout the spinal cord. This was followed by neuronal loss at three months of age. All three
parameters continued to degenerate in the PPT1-/- spinal cord compared to the wild-type spinal
cord until PPT1-/- mice are terminal. The finding of widespread spinal cord disease was
recapitulated in autopsy samples from human INCL patients (Nelvagal et al, In preparation).
These data suggest that PPT1-/- leads not only to the progression of INCL, but may also
influence neurodevelopment.
In the spinal cords of intracranial-treated mice, the disease was not treated regardless of
which AAV vector was used. In this study, we showed that there was accumulation of AFSM,
and an increase in histological markers of disease (CD68 and GFAP) when treatment was limited
to the brain. This led to the hypothesis that treating the spinal cord directly via gene transfer
techniques would prevent disease. This also led to the second hypothesis that treating PPT1-/-
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mice by both intracranial and intrathecal routes would significantly improve the histology,
improve motor function, and extend the lifespan as compared to either treatment alone.
There appears to be a reciprocal response when comparing intracranial to intrathecal
injections in PPT1-/- mice. When PPT1-/- mice are treated with intracranial AAV2/9-hPPT1, the
disease in the brain is corrected, however the spinal cord remains diseased. In contrast, when
PPT1-/- mice are treated with intrathecal AAV2/9-hPPT1, the disease in the spinal cord is
corrected whereas the brain is still affected. A biochemical surrogate for therapeutic efficacy is
decreased secondary elevations of other lysosomal enzymes. Secondary elevations of βglucuronidase in the brain are significantly reduced in intracranial-injected mice alone and only
slightly improved in intrathecal-injected mice. The lack of biochemical improvement in the brain
following intrathecal injection was somewhat surprising given that two to five percent of wildtype PPT1 activity levels in the brain were detected throughout the study. It has been shown that
a very small percentage of wildtype lysosomal enzyme activity levels are required to correct the
disease pathology (Sands et al, 1994). In the regions targeted by gene therapy, there was a
decrease in histological markers of disease (AFSM, CD68, and GFAP). Particularly in
intracranial-injected animals, there were improvements in gross physiology (cortical thickness,
brain weight) which was not observed in the intrathecal-injected mice alone. When cytokine
levels were examined in the brain, there was a decrease in cytokine/chemokine levels in the brain
of intracranial treated mice but not in the intrathecal alone. Interestingly, in the intrathecalinjected mice alone, there was still an upregulation of cytokines/chemokines, which may be due
to circulating neuroinflammatory factors in the cerebral spinal fluid. When either disease region
was targeted, there was an improvement in motor function and an extension in lifespan. The
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histopathology of the treated mice suggest that disease outside of the treated regions could
explain the reduced motor function and reduced lifespan as compared to wild-type mice.
When these diseased regions were targeted in combination, there was a significant
decrease in histological markers of disease in the brain and spinal cord. Furthermore, there was a
return in neuroinflammatory factors in the brain to wild-type levels. There was also a significant
improvement in gross brain anatomy. Overall, there was a dramatic and significant improvement
in motor function and extension in lifespan. The combination intracranial and intrathecal-injected
mice are by far the longest-lived treated PPT1-/- mice (22 months) reported to date.

Conclusion from combination therapy
The identification and characterization of the spinal cord disease and the efficacy of
targeting the spinal cord with AAV-based gene therapy are two overarching findings of these
studies. First, the disease in the spinal cord begins early in the pathogenesis of INCL. In fact,
significant disease in the spinal cord begins about one month earlier than disease in the brain. For
therapeutic purposes, this argues for early treatment of the spinal cord. Moreover, our study also
shows that persistent expression of PPT1 in the spinal cord is necessary for an extension in the
quality of life of PPT1-/- mice. A previous study where enzyme replacement was delivered
intrathecally in PPT1-/- mice showed that lifespan was only extended by one month. Taken
together, these two aspects suggest that proper identification and treatment for INCL must begin
early in life (newborn screening) with methods that supply persistent PPT1 to the entire central
nervous system.
Second, while INCL disease has primarily been seen as a brain disease, our work
demonstrates that it is necessary to evaluate the disease in the context of the entire central
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nervous system. As we have shown, targeting the entirety of the central nervous system
significantly improves motor function and lifespan of the PPT1-/- mice and slows the
progression of INCL-related disease. While intracranial and intrathecal administration of
AAV2/9 showed broad distribution in the central nervous system, the histochemical stain
determined that the mid-brain was not targeted. Subsequent analysis of this region in treated
mice showed significant disease that appeared only minimally decreased upon combination
therapy. Recent studies have employed the intrathecal route as a means to target the brain (Gray
et al, 2013; Guo et al, 2016; Hordeaux et al, 2015; Schuster et al, 2014). As our study suggests,
when using single-stranded AAV2/9 (ssAAV2/9) for intrathecal gene therapy, the correction of
the brain is minimal. Therefore, to target the entirety of the central nervous system, it is
necessary to utilize multiple routes of injection or to develop vectors that will be better
distributed within the brain parenchyma (see Future Directions). Since PPT1 is ubiquitously
expressed, it is also necessary to evaluate the disease outside of the central nervous system such
as the peripheral and autonomic nervous systems. Given the cardiac dysfunction and metabolic
abnormalities associated with INCL, it is also necessary to understand whether neuronal
dysfunction plays a vital role in these aspects of disease (see Future Directions).
In a more global context, infantile NCL is one of more than 14 different NCLs. While the
age of onset varies depending on the genetic mutation, the accumulation of AFSM, the increase
in histopathological markers of disease, the progression of disease within the brain, and the
overall clinical signs are relatively similar. The findings from our study along with Nelvagal et
al. moves the field forward by broadening the focus of NCL diseases from the brain to the
entirety of the central nervous system. It is not difficult to hypothesize that these NCLs would
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also have progressive spinal cord disease and that treatment for the NCLs will need to include
treatment of the spinal cord.

Future Directions for INCL gene therapy
Developmental defect in the spinal cord and peripheral nervous system disease
Our data, in combination with Nelvagal et al, suggest that there may be a developmental
component to INCL particularly in the white matter tracts of the spinal cord. It has been
previously shown that there is developmental-dependent PPT1 mRNA expression in the rat brain
in early life (Isosomppi et al, 1999; Suopanki et al, 2000; Zhang et al, 1999). This is not
surprising given that palmitoylation has been shown to play a key role in neurodevelopment and
neural function (Fukata & Fukata, 2010; Young et al, 2012). PPT1 has also been shown to be
localized throughout the axon and at synapses (Ahtiainen et al, 2006; Ahtiainen et al, 2003).
Furthermore, PPT1 deficiency in mice has shown altered synaptic vesicle recycling (Kim et al,
2008; Virmani et al, 2005). In Drosophila, PPT1 has been shown to regulate neural cell fate and
specification. In PPT1-/- larvae, there are a variety of defects in axonal guidance and branching
(Chu-LaGraff et al, 2010; Glaser et al, 2003). This suggests that PPT1 deficiency may alter
neuro-development.
While many studies have been conducted on the progression of INCL in mice after two to
three months, it is necessary to study the developmental defects of PPT1 deficiency either at
embryonic or early post-natal stages. It has been shown in Drosophila that the defects in axonal
guidance and targeting affect the entire nervous system. The visualization of axonal guidance
and targeting can be addressed with the development of the Thy1-YFP PPT1-/- reporter mouse
model. The Thy1-YFP reporter mouse labels some neurons of the motor and sensory cortex, the
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corticospinal tract, and the sciatic nerve. Furthermore, this reporter model has been used to
examine neuromuscular junctions. With the Thy1-YFP PPT1-/- reporter mouse model we will be
able to follow axonal guidance and targeting defects from the brain to the signaling endpoint. By
comparing the PPT1-/- mice to the wild-type littermate, we may begin to unravel how PPT1
deficiency contributes to the functional deficits at the cellular level.

Synergy of spinal cord and brain directed therapy
It is necessary to understand the role of the entire central nervous system in disease
progression. As shown, while targeting the brain or the spinal cord individually led to modest
increases in lifespan and function, targeting both regions simultaneously significantly improved
histological and clinical parameters compared to either region alone. In fact, targeting both
regions of the CNS leads to an apparent synergistic effect. If the two routes of administration
resulted in an additive effect, the median lifespan would have been approximately 17 months.
However, the lifespan of mice treated with both intrathecal and intracranial injections was 19.3
months. A similar synergistic effect was observed with motor function. An additive effect would
have resulted in motor deficits presenting at 11 months. However, significant motor deficits were
not observed until 15 months. A more thorough understanding of this synergy could guide the
future development of more effective therapies.
AAV2/9 has been shown to target a variety of cell types, particularly during the early
post-natal periods (Foust et al, 2009). To understand the synergy, it may be necessary to limit the
expression of PPT1 to select cell types such as neurons or glia using cell-specific promoters in
the AAV cassette instead of the ubiquitous CAG promoter. However, utilization of AAV may
not correct the entirety of each cell type leading to potential confounding results. To ensure
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broad expression of PPT1, it may be more beneficial to develop a mouse model where there
could be cell-specific expression of PPT1. We have made significant strides in the development
of this model (see Chapter 3: Cell-specific Expression of PPT1).
The synergy that we observed may be due to both a better distribution of PPT1
throughout the central nervous system as well as to the peripheral nervous system. It has been
shown that intrathecal injection of an AAV vector can result in significant expression in the
peripheral nervous system (Federici et al, 2012; Jacques et al, 2012; Vulchanova et al, 2010).
The peripheral and autonomic nervous systems in PPT1 deficient animals have not been
characterized. It will be important to examine the impact of CNS-directed gene therapy on the
peripheral nervous system. Performing gene therapy experiments in the Thy1-YFP PPT1-/reporter mouse model might provide insights into the consequences of this approach on the
peripheral nervous system. Finally a thorough biochemical, histological, and functional
assessment of the systemic disease in AAV-treated mice might be informative..

Improved Combination Therapies
Combination therapy in lysosomal storage diseases has shown tremendous promise
(Hawkins-Salsbury et al, 2011). By expanding the region targeted by CNS-directed gene therapy,
we were able to more than double the lifespan of PPT1-/- mice. By targeting regions of the
central nervous system not previously corrected, we were able to significantly delay disease
onset. However, the lifespan of the combination treated animals were still shorter than the wildtype littermates. There is still much more to be accomplished in order to completely correct the
disease. In order to treat INCL and other storage disorders effectively, it will be necessary to
correct the entirety of the system or organ and not simply a small portion. While ‘cross-
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correction’ is a relatively efficacious method to deliver enzyme, it’s radius of correction is
limited.
The use of AAV viral vectors to target the CNS in INCL has been beneficial due to the
distribution of the AAV vector within the parenchyma. With improving CNS-specific vector
serotypes, the distribution of the vectors will only improve. As we showed with the histological
stain for PPT1, the PPT1 staining is broad and diffuse throughout the CNS. However, one region
that has marginal staining is the thalamus and mid-brain region. The thalamic region has been
shown to be the first area affected in INCL with both neuronal loss and glial activation. The
thalamic region appeared to have only minimally decreased histological markers of disease in the
combination-treated animals and there was no decrease in the animals receiving individual
treatments. This suggests yet another therapeutic target using AAV2/9 gene therapy. Another
method to target the thalamus would be to employ another AAV vector serotype (e.g. AAV-DJ)
or a self-complementary AAV that has a broader distribution and increased transduction
efficiency (Fu et al, 2003; Mao et al, 2016).. In either case, this could lead to an increase in the
level of enzyme produced and broader correction.
Small molecule drugs have been explored to replace PPT1 activity (PPT1 mimetics) or
target secondary effects of PPT1 deficiency (neuroinflammation). Unfortunately, these small
molecule therapies have resulted in little to no improvement in functional parameters of INCL
such as motor function or longevity. For example, using the anti-inflammatory Minozac, there
were minor improvements in histological markers of disease in the brain but functional tests
remained unchanged (Macauley et al, 2014). Similarly, using a PPT1 mimetic,
phosphocysteamine, there was no biochemical, histological, or functional improvements in INCL
mice (Roberts et al, 2012). Although these small molecule drugs provide little or no benefit on
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their own, they might interact with another form for therapy (e.g. gene therapy) to greatly
increase efficacy.
INCL is considered primarily a neurological disease. However, systemic disease is
present in mice and could be relevant for humans (Galvin et al, 2008; Woloszynek et al, 2007). If
treatment is limited to the CNS, then the systemic disease could become clinically relevant. To
tackle systemic disease, enzyme replacement studies have shown that intravenous delivery of
recombinant PPT1 corrects INCL histopathology in the visceral tissues however this does not
significantly improve outcome measures such as lifespan or motor function (Hu et al, 2012).
Therefore, to treat INCL disease in its entirety, it may be necessary to combine CNS-directed
gene therapy with recombinant enzyme replacement therapy.
Another combination therapy that may be useful is gene therapy in combination with
substrate reduction. Substrate reduction therapy (SRT) is accomplished by inhibiting the
synthesis of the substrates for the enzyme that is deficient. Although in principle SRT is not
predicted to stop the disease, it could slow the accumulation of undegraded substrates and
potentially slow disease progression. SRT is currently in clinical trials for several LSDs (Cox,
2005; Pastores, 2010; Valayannopoulos, 2013). Therefore, SRT might be an ideal adjunct
therapy for INCL. In fact, dramatic results have been achieved in the mouse model of Krabbe
disease by combining SRT with CNS-directed gene therapy (Hawkins-Salsbury et al, 2015). SRT
could be utilized in INCL by targeting the palmitoylation of proteins. Within the cell, the
dynamics of palmitoylation is in equilibrium and has been shown to involve DHHC proteins and
acyl-protein thioesterases (Fukata et al, 2015; Fukata et al, 2013; Fukata & Fukata, 2010; Fukata
et al, 2016; Martin et al, 2012). Ultimately, palmitoylated proteins are degraded in the lysosome.
Therefore, to reduce the influx of palmitoylated proteins into the lysosome, one method could be
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a reduction in the cellular pool of free palmitate. Palmitate is produced in the cell by the
multimeric enzyme fatty acid synthase (Smith et al, 2003). Inhibition of palmitate synthesis can
be accomplished by using small molecule drugs that competitively inhibit fatty acid synthase
(Abdel-Magid, 2015). There are a number of FASN inhibitors such as the C75 (a cerulenin
derivative), orlistat, and epigallocatechin-3-gallate (EGCG, green tea derived). When combined
with CNS-directed gene therapy, it could be possible to attenuate the severity of the disease.

Summary of cell-limited study of PPT1
Given the complex nature of INCL, this study sought to develop a model where INCL
could be studied in a cell-specific manner. The cell-specific study of INCL is hindered by ‘crosscorrection’. For example, correction of neurons with soluble PPT1 would ultimately correct the
neighboring glia making the interpretation of the results inconclusive. To prevent crosscorrection, we tethered PPT1 to the lumen of the lysosome. This was done by genetically
engineering the human PPT1 cDNA to the C-terminus and transmembrane domain of the
lysosomal-associated membrane protein-1 (LAMP1).
In this study, PPT1 was tethered to the C-terminus of LAMP-1 using a six-glycine linker.
We showed that the PPT1-LAMP1 chimeric protein retained enzymatic function and was
incapable of ‘cross-correction’ in vitro. We developed lentiviral constructs that expressed either
wild-type human PPT1 or the chimeric PPT1-LAMP1 and transduced PPT1-deficient cells. We
showed that PPT1-LAMP1 had similar enzymatic activity as the wild-type PPT1. Using a
transwell setting, we further show that PPT1-LAMP1 was incapable of ‘cross-correcting’
deficient cells in the transwell insert.
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Since our overarching goal was to express PPT1 in a cell-specific manner, we sought to
limit PPT1-LAMP1 expression to particular cell types. Therefore, we employed current
transgenic technology using the Cre-loxP system. We genetically inserted PPT1-LAMP1 into a
transgene driven by the ubiquitous CAG promoter. For cell-specificity, we inserted a LoxPSTOP-LoxP sequence within the transgene. This system functions properly in vitro. Therefore,
we proceeded to create animals harboring this Cre-responsive transgene. A preliminary
examination of Founder #42 (F42) revealed PPT1 activity throughout the mouse with
supraphysiological levels detected in the brain and heart, and low levels in the liver. This global
activity in the absence of Cre recombinase would not allow for cell-specific expression in vivo.
Ultimately, we decided to characterize F42 as a proof-of-concept model. We showed that
PPT1-LAMP1 is expressed in vivo and that it is localized to the lysosome. Using a transwell
system, we showed that PPT1-LAMP1 is not secreted from primary dermal fibroblasts derived
from F42. This is further confirmed in vivo upon examination of the liver. While there were low
levels of enzymatic activity in the liver, we observed the hallmark of INCL disease, AFSM, in
sporadic cells throughout the liver such as in the hepatocytes and Kupffer cells. This indicated to
us that PPT1 is not being secreted and taken up by neighboring cells. Expression of PPT1LAMP1 corrected all of the INCL clinical signs measured such as visual deficits as measured by
ERGs, motor function via rotarod, and lifespan. This shows that expression of PPT1-LAMP1 can
complement native soluble PPT1.

Conclusions from cell-specific expression of PPT1
We have generated a model that has cell-limited but ubiquitous expression of PPT1. This
was most likely due to a spontaneous recombination of the loxP-STOP-loxP within the transgene
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as was detected by PCR analysis of the genome. While this model cannot be used for the
intended purpose, the model instead can be used to study in vitro effects of sequestered PPT1.
Cell-specific studies can still be conducted in a mixed culture setting (discussed further in Future
Directions). We have shown that it is possible to sequester a soluble lysosomal hydrolase within
the lysosome and that this sequestration does not impede the ability of the enzyme to function.
Therefore, with some modifications, it may be possible to express PPT1-LAMP1 in a cellspecific manner and begin to understand the role of different cell types in INCL. On a grander
scale, this conceptual approach can be applied to a variety of lysosomal storage disorders that
result from deficiencies in a soluble lysosomal hydrolase (e.g. Krabbe disease, MPS disorders).
These LSDs suffer from the same confounding nature of ‘cross-correction’. By better
understanding the pathogenesis of these LSDs and the major cell types that are affected, we may
begin to develop more targeted therapies.

Future Directions for Cell-specific Study of INCL
Modification of the Transgene
‘Cross-correction’ remains a hindrance to the study of specific cell types in lysosomal
storage diseases. The generation of the PPT1-LAMP1 chimeric enzyme prevents ‘crosscorrection’ as we have shown. While the F42 model for PPT1-LAMP1 expression may be useful
for in vitro studies, for cell autonomous studies of INCL in vivo, the model is still lacking. The
original concept of utilizing the Cre-loxP system for cell-specific expression of PPT1-LAMP1
could still prove to be the most useful. One scenario that may have contributed to spontaneous
recombination of the loxP sites in F42 is the methodology in the generation of the transgenic
mice. We utilized a conventional transgenic approach where our transgene was micro-injected
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into mouse embryos. This method is prone to concatamer formation at a variety of integration
sites. The concatamers in turn might be prone to recombination particularly with large regions of
repeat sequences. To prevent this, we could take advantage of the ROSA locus. The ROSA26
locus has been shown to be targeted with high efficiency and can be limited to a single copy of
the transgene (Beard et al, 2006; Zambrowicz et al, 1997).
It has additionally been shown that a strong promoter can read-through a loxP-STOPloxP sequence. While infrequent, this could also lead to confounding results. One scenario to
overcome this problem would be to utilize the double-floxed inverted orientation (SmedemarkMargulies & Trapani, 2013; Sohal et al, 2009). This system utilizes two sets of incompatible
loxP sites that flank the inverted transgene, and, when subjected to Cre-recombinase, result in an
inversion of the transgene to its functional form. This method would not require the presence of a
STOP sequence in the transgene and any spontaneous recombination would not result in a
functional transgene.
Finally, we could re-engineer our transgene to contain loxP sites outside of the expression
cassette. In this strategy, we would have ubiquitous expression in the absence of Cre
recombinase but could ‘turn-off’ the expression in a cell-specific manner.

Mixed culture studies
While the current model cannot be used for in vivo examination of specific cell types in
INCL, in vitro studies can be conducted using mixed cultures. We have developed lentiviral
vectors that express either hPPT1-LAMP1 or wild-type hPPT1, and an empty vector control. The
PGK promoter, a ubiquitous promoter, drives the transgenes in these lentiviral vectors.
Moreover, there is a selectable puromycin marker. It will be possible to transduce specific cell
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types (e.g. neurons, astrocytes) from PPT1-/- animals and by co-culturing these cells with other
cell types, begin to understand how PPT1 deficiency affects intra- and inter-cellular interactions.
For example, we may begin to understand the PPT1-/- neuronal phenotype by co-culturing
PPT1-/- neurons with lentiviral-transduced PPT1-/- astrocytes in vitro. Similar studies can be
conducted using isolated primary cell cultures from the F42 transgenic line.
To mimic in vivo settings, we could change the promoter of these lentiviral vectors from
a ubiquitous promoter to cell-specific promoters. We could inject these lentiviral vectors into
newborn mouse brains. While this will not allow for the targeting of every cell for a specific cell
type, it will allow for the study of a specific cell type in a defined region. For example, the
lentiviral vectors could be injected in the thalamus of PPT1-/- animals, one of the first sites of
CNS disease, and these animals could be later observed for changes in biochemistry, histology,
and clinical parameters.
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